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CHAPTER 1: INTRODUCTION 
Section I: Overview of herpesviruses 
Herpesvirales.  The Order Herpesvirales consists of three virus families: the 
Alloherpesviridae: herpesviruses of fish and amphibians, the Herpesviridae: herpesviruses of 
mammals, birds, and reptiles, and the Malacoherpesviridae: herpesviruses of mollusks. 
Herpesviruses are linear, single-segment, dsDNA viruses.  Classification as a herpesvirus is 
dependent on the structure of the virus particle (virion).  Herpesvirus virions consist of an 
envelope, tegument, icosahedral capsid, and viral DNA core (Fig. 1-1).  These viruses obtain their 
envelope, a lipid bilayer embedded with glycoproteins, from their hosts during secondary 
envelopment.  The glycoproteins interact with cell surface markers to initiate entry into target cells 
(74).  Directly beneath the envelope lies a layer of proteins and RNA, the tegument, that is only 
present in herpesviruses.  These molecules immediately begin modulating the cellular environment 
to facilitate virion production upon entry (65, 94).  Within the tegument lies the capsid, a protein 
shell that surrounds the viral DNA.  The capsid primarily consists of the major capsid protein 
(MCP) organized into an icosahedral (20 faces) shape, with T=16 symmetry.  Surrounded by the 
capsid is the viral DNA core.  The DNA lacks chromatin and is packed into the shape of a ring 
called a torus.  The DNA is packed so tightly into the capsid that it is pressurized, which is believed 
to assist with injection of the DNA into the nuclear pore of infected cells (74).  
Disease manifestations.  Herpesviruses produce new virions through a lytic replication 
cycle that results in the death of the host cell.  These viruses also establish life-long infections 
within their hosts through latency: a state in which lytic replication is repressed and no new virions 
are produced.  From latency the viruses can return to a lytic replication cycle through reactivation 
which usually occurs due to cellular stressors such as changes in nutrients, damage, etc.  Across 
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the various hosts, symptoms of herpesvirus infections may include fever, lesions, inflammation, 
cancer, or death primarily in immunocompromised or immunodeficient populations. Disease in 
immunocompetent individuals usually ranges from none to mild cold or flu symptoms, may 
include some of the symptoms mentioned above, and rarely leads to death.  However, there are 
exceptions.  During organ transplantations, seemingly healthy, immunocompetent individuals can 
experience severe disease and/or death if the organs are infected with human cytomegalovirus 
(HCMV), a member of the Herpesviridae (48, 58, 74, 91, 105). 
Lytic replication cycle.  The lytic replication cycles of all herpesviruses are similar, 
consisting of the same basic steps (Fig. 1-2) (21, 74).   
Attachment and entry.  Herpesvirus infection begins with attachment of virion envelope 
glycoproteins (typically gB and others), to cell surface receptors heparan sulfate proteoglycans on 
permissive cells (Fig. 1-2, steps 1 and 2).  Upon the receptor/ligand interactions, the virion enters 
the cell by either viral envelope fusion with the cellular membrane or endocytosis (Fig. 1-2, step 
3).  After membrane fusion the capsid and tegument are released into the cytoplasm (Fig. 1-2, step 
4).  During endocytosis, the capsid and tegument are not released into the cell until the viral 
envelope fuses with the membrane of the intracellular vesicle.  Once in the cell, the capsid is 
trafficked along microtubules to the nucleus (Fig. 1-2, step 5a).  Meanwhile, the tegument proteins 
begin modulating the cellular environment to facilitate production of new virions (Fig. 1-2, steps 
5b and 6).  At the nucleus, the capsid is docked to a nuclear pore by unknown mechanisms.  With 
the capsid portal facing the nuclear pore, the viral DNA is propelled into the nucleus, possibly due 
to the potential energy of the capsid during DNA packaging (Fig. 1-2, step 7) (74).   
DNA replication and viral cascade of gene expression.  Once the viral DNA is in the 
nucleus, the viral cascade of gene expression begins starting with the immediate early (alpha) 
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genes.  Herpesvirus immediate early genes require no de novo protein synthesis and are 
immediately transcribed in the nucleus and the transcripts translocated to the cytoplasm for 
translation (Fig. 1-2, steps 9 and 10).  The products of immediate early genes are translocated to 
the nucleus to initiate transcription of early (beta) genes (Fig. 1-2, step 10).  Once translated, some 
early gene products remain in the cytoplasm, while others are transported to the nucleus to initiate 
viral DNA replication and transcription of late (gamma) genes (Fig. 1-2, steps 11-14).  Some late 
gene products are translocated to the nucleus for capsid assembly and egress, membrane-associated 
proteins are translated in the endoplasmic reticulum, and others such as tegument proteins are 
translated in the cytoplasm (Fig. 1-2, steps 15-17) (74).   
Assembly, tegumentation, and egress.  Capsid assembly begins in the nucleus and is also 
where the inner tegument consisting of pUL32 (pp150, “pp” denotes phosphoprotein), is acquired 
(Fig. 1-2, step 18).  Capsids then traverse the nuclear envelope using the nuclear egress complex 
(NEC), viral proteins that destabilize the nuclear membrane (Fig. 1-2, steps 19-20).  Once in the 
cytoplasm, the partially tegumented capsid acquires its outer tegument by interacting with large 
aggregates of tegument proteins.  These large aggregates are usually near membranes of various 
sizes and Golgi origin (trans Golgi networks, TGN) (Fig. 1-2, step 21).  After acquiring its full 
tegument, the capsid acquires its envelope by budding into TGN membranes, becoming a fully 
infectious virion (Fig. 1-2, step 22).  The vesicle containing the virion, an exocytic vesicle, can 
carry one or multiple virions at a time.  Within the vesicles, virions are trafficked to the cellular 
membrane for egress into the extracellular environment (Fig. 1-2, steps 23-24) (74, 75). 
Herpesviridae.  The Herpesviridae, herpesviruses of mammals, birds, and reptiles, consists 
of three subfamilies: the Alpha-, Beta-, and Gammaherpesvirinae.  These subfamilies are grouped 
on the basis of their host ranges, length of reproductive cycles, ability to cause infection in cell 
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culture, destruction of infected cells, and cells in which they establish primary infections and 
latency (Table 1-1).  Individual viruses within the Alphaherpesvirinae tend to have a broad host 
range, relatively short reproductive cycles, infections spread rapidly in cell culture, infected cells 
are efficiently destroyed, they infect primarily mucocutaneous tissue, epithelial cells, and 
fibroblasts, and establish latency primarily within the dorsal root ganglia of neurons (15, 74).  
Individual viruses within the Betaherpesvirinae have a narrow host range, long reproductive 
cycles-for some over seven days, infections progress slowly in cell culture, infected cells are 
frequently enlarged (cytomegalia), they primarily infect fibroblasts, T, endothelial, epithelial cells, 
etc., and establish latency primarily within lymphoid tissues, hematopoietic progenitor cells, and 
other tissues (22, 64, 74, 99).  Individual viruses within the Gammaherpesvirinae have a host range 
that is restricted to the family or order of the natural host, in cell culture they infect lymphoblastoid 
cells, primarily infect and establish latency within B, T, epithelial, and endothelial cells, among 
others, infections hardly damage cells except during reactivation from latency, and they can induce 
lymphoproliferation and cancers in infected cells.  Unlike other herpesviruses, latency is the 
default infection strategy for most gammaherpesviruses, so information regarding their lytic 
replication cycles is limited (18, 55, 74, 101).  
Human herpesviruses and disease manifestations.  There are nine herpesviruses of 
humans across the three subfamilies.  The human alphaherpesviruses include herpes simplex virus 
1 (HSV-1), herpes simplex virus 2 (HSV-2), and varicella zoster virus (VZV).  The human 
betaherpesviruses include human cytomegalovirus (HCMV), human herpesvirus 6A, 6B, and 7 
(HHV-6A, -6B, -7).  The human gammaherpesviruses include Epstein-Barr virus (EBV) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV).  HSV-1 and HSV-2 are closely related viruses 
that cause oral and genital lesions, along with other more serious diseases such as encephalitis and 
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meningitis.  VZV causes chicken pox in children and upon reactivation in older individuals causes 
shingles.  Chicken pox is an itchy rash that spreads all over the body.  Shingles is a painful rash 
that occurs in localized areas of the body.  HCMV is an opportunistic pathogen that causes a range 
of symptoms from none to life-threatening.  The most severe symptoms include organ-specific and 
systemic inflammation.  Human herpesvirus 6A, 6B, and 7, which are more closely related than 
the simplex viruses, cause a range of symptoms as well, from asymptomatic infection to febrile 
illnesses, with some associated with neurologic complications, seizures, and encephalitis (50, 67, 
100).  EBV causes infectious mononucleosis, lymphoproliferative diseases, endemic Burkitt 
lymphoma, Hodgkin disease, nasopharyngeal carcinoma, as well as other B cell cancers in 
individuals with immunodeficiencies.  KSHV causes Kaposi sarcoma, primary effusion 
lymphoma, and various lymphoproliferative diseases (67).  
Section II: Overview of HCMV 
HCMV significance.  HCMV is a global pathogen, with the up to 85% of adults infected 
by the age of 40.  It causes organ-specific and systemic inflammation that leads to severe disease 
in immunocompromised (transplant recipients, HIV patients) and immunodeficient (fetuses, 
infants) individuals.  The immunocompromised populations tend to suffer from hepatitis, 
pancreatitis, pneumonitis, enteritis, retinitis meningitis and encephalitis.  The disease usually 
manifests in immunodeficient populations as liver, lung, and spleen problems, petechiae, hearing 
loss, and neurodevelopmental disabilities (64, 67).  HCMV is the most common viral congenital 
infection, as well as the leading cause of birth defects and childhood disabilities in the United 
States (49, 67).  In fact, more children suffer from CMV-related diseases than from more well-
known congenital conditions such as Down syndrome, fetal alcohol syndrome, or spina bifida (16).  
The virus is also the most common, non-hereditary cause of hearing loss in children (43).   
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HCMV virion characteristics.  The virion is ~2000 Å	in	diameter; the tegument consists 
of at least 38 different proteins (including some of cellular origin) present in various quantities; 
the capsid has a diameter of ~1300 Å, and surrounds a genome ~236 kb that encodes at least 167 
proteins, four large noncoding RNAs, two oriLyt RNAs, and at least 23 microRNAs.  HCMV is 
the largest virus that infects humans, in terms of the size of its genome (73).  HCMV utilizes its 
various gene products to manipulate the cellular environment into one most favorable for new 
virion production (20, 64).   
HCMV replication cycle.  The HCMV lytic replication cycle resembles that of other 
herpesviruses, but with some unique aspects (64). 
HCMV cellular tropism and receptors.  HCMV infects a variety of cells including 
fibroblasts, monocytes/macrophages, neutrophils, hepatocytes, endothelial, epithelial, smooth 
muscle, stromal, and neuronal cells.  This broad cellular tropism is why HCMV causes such severe 
disease and is hard to treat.  This broad tropism also suggests that HCMV either possesses one 
broad common receptor, multiple cell-specific receptors, or a receptor complex that consists of a 
combination of both cell-specific and broadly expressed cellular receptors.  Several receptors, in 
addition to heparan sulfate, have been investigated and none have been shown to conclusively be 
involved in making cells permissive for HCMV infection (22, 64).  
Attachment and entry.  HCMV infection begins with attachment of virion envelope 
glycoproteins B, H, L, O, M, and N, as well as proteins pUL128, pUL130, and pUL131A in some 
instances, to cell surface receptors heparan sulfate proteoglycans on permissive cells.  Upon the 
receptor/ligand interactions, the virion enters the cell by either viral envelope fusion with the 
cellular membrane or endocytosis.  After membrane fusion the capsid and tegument are released 
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into the cytoplasm.  During endocytosis, the capsid and tegument are not released into the cell until 
the viral envelope fuses with the membrane of the intracellular vesicle (22, 64).   
I had primary responsibility for writing the following sections (pages 7-15), which 
were published as sections 9.3.1-9.3.4 and 9.4.3 in Close et al. 2018 Advances in Experimental 
Medicine and Biology (20). 
Tegument proteins in action.  Once in the cell, tegument proteins begin modulating the 
cellular environment to facilitate production of new virions.  As mentioned earlier, HCMV virions 
contain at least 38 different tegument proteins in varying quantities.  Tegument proteins are 
important for many processes throughout infection, including disassembly of virions, 
transcriptional regulation, modulation of cellular responses, and virion maturation.  Many, if not 
most tegument proteins, perform multiple, distinct functions.  Although it lacks a well-defined 
structure, there are clear elements of structural order throughout the tegument.  Tegument protein 
pUL83 (pp65) is the most abundant protein in HCMV virions and dense bodies.  While not 
required for replication, pp65 is important for the initiation of infection by enhancing activation of 
the major immediate-early promoter and is important for recruiting proteins into the virion during 
assembly.  pUL48 (large tegument protein, LTP,) is the largest and second most abundant HCMV 
tegument protein.  It is essential for replication and is involved in the release of viral DNA from 
the capsid. pUL32 (pp150) is the third most abundant tegument protein.  It is essential for viral 
replication and plays a role in stabilizing DNA-containing capsids during virion maturation by 
forming the inner tegument.  pUL47 (LTP-binding protein, LTPbp) is an essential protein involved 
in uncoating the capsid.  pUL103 is a low-abundance tegument protein that plays important roles 
late in HCMV infection, including cVAC biogenesis, cell-to-cell spread, and virion maturation.  
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pUL103 may have roles early in the HCMV replication cycle due to its presence in nuclei and 
interactions with several proteins of the innate immune system (20).  
Capsid trafficking and uncoating.  The capsid is trafficked along microtubules to the 
nucleus.  At the nucleus, the capsid is docked to a nuclear pore by unknown mechanisms.  With 
the capsid portal, consisting of pUL104, facing the nuclear pore, the viral DNA is propelled into 
the nucleus, possibly due to the potential energy of the capsid during DNA packaging.  These 
processes occur with assistance from pUL48, pUL47, and the smallest capsid protein (SCP) 
pUL48A (64).   
DNA replication and viral cascade of gene expression.  Once the viral DNA is in the 
nucleus, the viral cascade of gene expression begins starting with the immediate early (alpha) 
genes.  HCMV immediate early (alpha) genes require no de novo protein synthesis and are 
transcribed and translated immediately upon entering the nucleus.  The products of immediate 
early (alpha) genes are translocated to the nucleus to initiate transcription of beta genes.  Once 
translated the early (beta) gene products are transported to the nucleus to initiate viral DNA 
replication and transcription of late (gamma) genes.  Some late gene products are translocated to 
the nucleus for capsid assembly and egress, membrane-associated proteins are translated in the 
endoplasmic reticulum, and others such as tegument proteins are translated in the cytoplasm (74).  
Capsid components and assembly.  During capsid assembly, a protein scaffold, 
consisting of the HCMV assembly protease (PR-pUL80a, Table 1-2) and assembly protein 
precursor, (pAP-pUL80.5, Table 1-2) forms.  The protease and assembly protein precursor are 
encoded by the same gene and share the same carboxyl terminus, which contains domains 
necessary for interaction with the major capsid protein (MCP-pUL86, Table 1-2).  These proteins 
also have conserved amino terminal domains important for self-assembly into a scaffold, around 
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which the capsid proteins assemble.  Capsid proteins are the building blocks of capsids with the 
major capsid protein (MCP, Table 1-2) as the major component.  During assembly, MCP forms 
both pentameric and hexameric capsomeres, the major subunits of capsids (Fig. 1-3).  Capsomeres 
are cylindrical and have a pore that runs along their length, which is ~160 Å.  Capsomeres self-
assemble onto the scaffold to form a capsid with T = 16 icosahedral symmetry.  In this 
arrangement, 150 hexons form the triangular faces of the capsid and 11 pentons make up the 
vertices of those triangles (Fig. 1-4).  Given that there are 6 molecules of MCP in each of the 150 
hexons and 5 molecules of MCP in each of the 11 pentons, there are a total of 950 molecules of 
MCP per capsid.  The twelfth pentonal position is occupied by a complex formed by 12 copies of 
the portal protein (pUL104 or PORT, Table 1-2), which provides the channel necessary for 
packaging the viral genome into the capsid during assembly and for its release into the nucleus at 
the initiation of infection.   
During DNA encapsidation, the portal complex interacts with the terminase complex, 
which consists of ATPase (pUL89 or TER 1, Table 1-2) and DNA recognition (pUL56 or TER 2, 
Table 1-2) subunits.  The small capsid protein (SCP-pUL48.5, Table 1-2) is the second most 
abundant protein in the HCMV capsid with 900 molecules per capsid. SCP is only found associated 
with the hexons, decorating their tips.  In the absence of SCP, nascent capsids are devoid of viral 
DNA and the capsid-associated tegument protein pUL32 (pp150; “pp” denotes phosphoprotein).  
In contrast, SCP is dispensable for HSV-1 viral growth, demonstrating virus-specific structural 
and functional roles for this protein.  Between the hexons and pentons reside small triplexes 
consisting of a dimer of the minor capsid protein (MnCP-pUL85, Table 1-2) and a monomer of 
the minor capsid-binding protein (MnCP-bp-pUL46, Table 1-2).  These triplexes are important for 
stabilizing the nucleocapsid.  The portal capping protein (PCP-UL77, Table 1-2) and the capsid 
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transport tegument protein (CTTP-pUL93) form the capsid vertex-capping (CVC) complex, also 
known as the capsid vertex-specific component (CVSC), which decorates pentons.  The terminase-
binding protein (TERbp-pUL51, Table 1-2) and the capsid transport nuclear protein (CTNP-
pUL52, Table 1-2) associate with this complex as well.  The role(s) of this complex and the 
associated proteins have not been determined, although they are thought to be involved with 
nucleocapsid stability by helping the capsid to withstand internal pressure from the DNA during 
encapsidation.  They are also thought to be involved in the release of viral DNA into the nucleus 
during initiation of infection.  In addition, the CVC and its associated proteins have been shown 
to be important for cleavage of concatemeric viral DNA into unit length genomes (20). 
Encapsidation of virus genomes.  Single copies of the virus genome are packed into 
newly formed capsids.  The major events during genome encapsidation are assembly and then 
degradation of the scaffold, packaging of the virus genome into the rigidly constrained space inside 
the capsid, cleavage of the genome precisely at its termini, and closure (or corking) at the portal 
of the highly pressurized capsid.  The virus accomplishes the process of DNA encapsidation 
rapidly, within fractions of a second.  As the protease disassembles the scaffold, a virus genome is 
threaded into the capsid, short terminus first, through the channel formed by the portal complex.  
The ATPase subunit of the terminase is the motor for translocating viral DNA into capsids.  For 
HCMV, the DNA recognition subunit of the terminase recognizes the intact packaging and 
cleavage sequence that is formed when pac-1 and pac-2 sequences at the genomic termini are 
juxtaposed in covalently circularized or concatemeric genomes.  Precise cleavage by the terminase 
results in packaging one complete virus genome per capsid.  Other viral proteins implicated in this 
process are pUL56 and pUL89.  pUL56 binds to AT-rich sequences within the pac sequences and 
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has nuclease activity.  pUL89 also has DNA cleavage activity; in addition to the terminase, it may 
be responsible for cleavage of the virus genome during encapsidation.   
Once the capsid is assembled, it becomes partially tegumented in the nucleus.  Proteins 
pUL32 and pUL48 form the inner tegument, an organized netlike layer that encloses the capsid 
shell.  The inner tegument proteins tightly associate with the capsid in a manner that is resistant to 
treatment with various detergents.  pUL32 interacts with the outside of the capsid in a manner that 
adds stability to the capsid, helping it to withstand the high internal pressure associated with the 
tightly packed genome (20). 
Nuclear egress.  Before capsids can enter the cytoplasm, they must pass through the 
nuclear envelope, which consists of the inner nuclear membrane (INM), the perinuclear space that 
is contiguous with the endoplasmic reticulum (ER), and the outer nuclear membrane (ONM).  In 
uninfected cells, the distance across the nuclear envelope, from inner membrane to outer 
membrane, is typically ~50 nm.  Nuclear envelope integrity is maintained by the linker of 
nucleoskeleton and cytoskeleton (LINC) complex, a multiprotein complex that directly connects 
the nuclear skeleton to the cytoskeleton.  The complex includes Sad1p, UNC-84 (SUN) and 
Klarsicht, ANC-1, Syne homology (KASH) domain proteins.  Interprotein interactions via SUN 
and KASH domains are important for nuclear membrane stability and for maintaining proper 
spacing between the inner and outer nuclear membranes.   
The nuclear envelope is further stabilized by the nuclear lamina, a proteinaceous network 
that lines the inner nuclear membrane.  Lamin proteins A/C and B associate with each other to 
form intermediate filaments that provide structural support to the cell.  Lamin B also interacts with 
integral membrane proteins such as the lamin B receptor, which helps to tether the nuclear lamina 
to the inner nuclear membrane.  To get past the nuclear lamina, herpesviruses employ conserved 
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proteins that make up the nuclear egress complex (NEC, pUL50-nuclear egress membrane protein 
(NEMP), pUL53- nuclear egress lamina protein (NELP), Table 1-2).  In HCMV- infected cells, 
these proteins localize on the interior of the nucleus on the side that faces the cytoplasmic virion 
assembly complex (cVAC).  The NEC competes with lamin proteins A/C and B for binding to 
each other, disrupting the lamina’s fibrillary network.  In addition, the NEC disrupts the binding 
of lamins to the nuclear envelope protein emerin, which links the nuclear lamina to the inner 
nuclear membrane.  pUL50 also interacts with the HCMV-encoded nuclear rim- associated 
cytomegaloviral protein (RASCAL) that is thought to be important for NEC-dependent 
degradation of the nuclear lamina.   
Additionally, the NEC recruits other viral and cellular proteins such as the viral protein 
kinase (pUL97) and cellular protein kinase C (PKC), both of which phosphorylate nuclear lamins, 
leading to destabilization and reorganization of the nuclear lamina.  pUL97 has also been 
implicated in the phosphorylation of p32, a nuclear lamina component that interacts with the lamin 
B receptor, further contributing to nuclear lamina destabilization.  These changes in the nuclear 
lamina facilitate egress of the capsids by allowing capsids to bud from the nucleus into the 
perinuclear space during primary envelopment.  In HSV-1, the NEC forms a hexagonal lattice 
along the INM leading to formation of invaginations in the membrane and budding of capsids into 
the perinuclear space.  X-ray crystallography showed that the HCMV NEC also forms hexameric 
rings, suggesting conservation of this invagination and budding activity across the herpesviruses.  
After enveloped capsids enter the perinuclear space, their membranes fuse with the ONM, and the 
capsids are released into the cytoplasm (20). 
Tegumentation.  Once in the cytoplasm, the partially tegumented capsid acquires its outer 
tegument by interacting with large aggregates of tegument proteins.  The precise order of addition 
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of tegument proteins to maturing virions is unknown, but some information is available.  
Acquisition of the outer tegument occurs through several mechanisms (Fig. 1-5).  Some tegument 
proteins aggregate in the cytoplasmic milieu and form complexes prior to incorporation in nascent 
virions. Others accumulate on membranes of various sizes and Golgi origin (trans Golgi networks, 
TGN).  The marriage of partially tegumented capsids and membrane- associated tegument proteins 
is consummated during secondary envelopment, which occurs throughout the cytoplasmic virion 
assembly compartment (cVAC) (20). 
Cytoplasmic virion assembly compartment (cVAC).  One of the staples of HCMV 
infection, that appears to be involved in virion assembly and egress, is the presence of the 
cytoplasmic virion assembly compartment (cVAC).  The cVAC is a juxtanuclear structure induced 
by HCMV and consists of cellular endosecretory machinery, primarily Golgi and early/recycling 
endosomes (Fig. 1-6).  HCMV organizes the Golgi into a ring-like structure with the endosomes 
primarily in the center of the ring.  Other secretory machinery such as late endosomes and the 
endoplasmic reticulum (ER) are located at the outermost edges of the cVAC.  The cVAC is 
positioned at the center of the microtubule organizing center (mTOC) and induces the 
characteristic kidney bean shape of the nucleus.  Within the cVAC, nascent capsids acquire their 
outer tegument, envelopes, and are trafficked to the cellular membrane for release into the 
extracellular milieu, indicating its significance in the HCMV replication cycle.  Each infected cell 
has one cVAC, even cells with multiple nuclei due to cell fusion (syncytia).  cVAC biogenesis is 
dependent on expression of several miRNAs and late proteins: pUL48, pUL94, pUL103, and 
gpUL132 (Table 1-2) (20, 106).  The cVAC is present in various cells in vitro, and unpublished 
data suggests this structure exists in tissues as well (17, 23, 28, 53, 87, 89). 
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Egress.  After acquiring its full tegument, the capsid acquires its envelope by budding into 
TGN membranes, becoming a fully infectious virion.  The vesicle containing the virion, an 
exocytic vesicle, can carry one or multiple virions at a time.  Within the vesicles, virions are 
trafficked to the cellular membrane for egress into the extracellular environment (74, 75). 
Current treatments.  There are five main medications for the treatment and prevention of 
HCMV infections: ganciclovir (GCV), valganciclovir (VGCV), cidofovir (CDV), foscarnet 
(FOS), and letermovir (LTV).  GCV, VGCV, CDV, and FOS all target viral DNA replication.  
LTV targets viral DNA packaging.  GCV was the first treatment approved for HCMV infections 
and is still the therapy of choice today.  GCV is used in the prevention of HCMV disease and for 
treatment in immunocompromised hosts as well congenitally infected infants.  GCV is a 
nucleoside analog.  After undergoing phosphorylation by the viral kinase pUL97 and several 
cellular kinases, GCV is able to inhibit viral DNA synthesis by competitive inhibition of 
deoxyguanosine triphosphate.  GCV has low bioavailability and necessitated the development of 
a proform of the drug, VGCV.  Both drugs can exhibit toxicity with symptoms including 
hematological abnormalities such as anemia, neutropenia, and thrombocytopenia.  CDV and FOS 
are both approved for the treatment of retinitis in AIDS patients caused by HCMV, and for use in 
cases where GCV resistance is present.  Both also are limited in their use by their nephrotoxicity.  
The toxicity of these drugs is partially due to drug interactions between these treatments and other 
medications taken by the patients (46).  Possible off-target effects on host cell DNA replication by 
these medications could also explain their toxic effects.  LTV is the newest treatment available for 
treating and preventing HCMV infections in transplant recipients.  This drug has been shown to 
be effective against several clinical and GCV-resistant strains and is well tolerated (10).  The 
approval of this drug is a move in the right direction of developing more specific, diverse, and less 
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toxic treatments for HCMV infections.  However, more work needs to be done in this area.  In the 
Pellett laboratory, we believe that the protein HCMV pUL103 (p stands for protein, referred to 
henceforth as pUL103) has the potential to be an effective antiviral target.   
Section III: Overview of pUL103 homologs and protein interaction partners 
Introduction.  pUL103 and its alpha- and gammaherpesvirus homologs (HSV-1 pUL7,  
EBV BBRF2, KSHV ORF42) have been studied and shown to be important for herpesvirus 
replication (Table 1-3); the same is true for the pUL103 interaction partner HCMV pUL71 and its 
homologs (HSV-1 pUL51,  EBV BSRF1, KSHV ORF55) (Table 1-3).  In the absence of these 
proteins, the viruses are attenuated.  These proteins have various roles throughout herpesvirus 
infections, and we believe with continued study these proteins have the potential to be antiviral 
candidates. 
Characteristics of HCMV pUL103 and pUL71 
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of pUL103.  The UL103 gene is located in the unique long region of the genome.  UL103 is a late 
gene, meaning it requires the expression of the immediate early and early genes for it to be 
transcribed and translated (64).  The UL103 gene product pUL103 is a small (249 amino acids 
(aa), ~27.39 kDa), conserved tegument protein, with homologs in all viruses within the 
Herpesviridae (72, 74).  When the protein sequences of pUL103 and its homologs were analyzed, 
it was shown that the average conservation score of the N terminus (residues 1-125), 3.8, is greater 
than that of the C terminus (residues 126-249), which is 2.3.  Thus, the N terminus is more 
conserved than the C terminus, indicating the importance of this region to the function of the 
protein (Fig. 1-7).  Within all pUL103 homologs is a conserved herpesvirus domain with the 
sequence G-F-x(8)-E-D-x-V-x(12)-R.  This domain is also present in the protein topoisomerase 
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III of fission yeast, suggesting that these proteins may interact with nucleic acids (41).  In addition 
to the conserved herpesvirus domain, the pUL103 protein sequence may contain a DEA(D/H) box 
and late “L” domains (Fig. 1-8).  DEA(D/H) box domains are important for allowing proteins to 
interact with and unwind DNA and RNA (42).  Late domains are motifs primarily found in the 
Gag proteins of retroviruses that allow for interaction with the endosomal sorting complexes 
required for transport (ESCRT) and their associated proteins, helping to facilitate membrane 
scission processes.  The putative late domains present in pUL103 appear to follow the motif 
LYPXnL that allows for binding to the ESCRT-associated protein ALIX (63, 72, 78).  More work 
needs to be done to validate the function of the putative domains. 
Localization of pUL103.  As a tegument protein, pUL103 is present in virions and dense 
bodies, enveloped tegument proteins.  Within these particles pUL103 makes up a very small 
fraction of the total amount of protein present, around 0.1% (102).  Thus, at the beginning of an 
infection there is very little pUL103 present, below the threshold of detection for techniques such 
as immunofluorescence.  Being a gamma gene product, expression of pUL103 ramps up later in 
infection.  At 120 hours post infection, the majority of pUL103 is present in the cytoplasm within 
the cVAC, with little in the nucleus (72).   
Roles of pUL103 in HCMV infection.  pUL103 is involved in virion and dense body 
egress, cVAC formation, cell-to-cell spread, and virion maturation.  In pUL103-knockout 
experiments, viral titer decreases between 100 and 10,000-fold (1, 35, 110).  In studies where 
viruses were used where protein expression of pUL103 was able to be regulated, knockdown of 
pUL103 results in decreases in cVAC formation, plaque sizes indicative of reduced cell-to-cell 
spread, and secondary envelopment, hampering virion maturation (26). 
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Protein interaction partners of pUL103.  A study from our laboratory where a dual 
proteomics approach was used identified several cellular and viral protein partners of pUL103.  
The cellular proteins that were identified were primarily those involved in immune system 
signaling e.g. ISG15, IFIT1, STAT1, and IFI16 and intracellular trafficking e.g. DYNLL1, COPA, 
COPB1, ALIX, and MYO1C.  The viral proteins that were identified were primarily those involved 
in associating with DNA e.g. pUL112/113, pUL34, pUL123 (IE2), pUL44, and pUL84 and other 
tegument proteins pUL56, pUL47, pUL45, and pUL71 (72).   
The interaction between pUL103 and pUL71 was previously demonstrated to occur outside 
the context of infection, with data showing that pUL71 helps pUL103 to localize to Golgi 
membranes.  During infection, the two proteins colocalize and are within close proximity to one 
another (38).  Studies of the HSV-1 and EBV homologs of these proteins (pUL7 and pUL51; 
BBRF2 and BSRF1) have shown these proteins interact during infection, providing further 
evidence that the HCMV proteins might as well (3, 80, 108).   
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of pUL71.  pUL71 is encoded by the UL71 gene located in the unique long region of the genome 
(64).  UL71 is an early gene, meaning it requires the expression of immediate early genes for it to 
be transcribed and translated.  The UL71 gene product pUL71 is a small (361 aa, ~39.71 kDa), 
conserved tegument protein, with homologs in all viruses within the Herpesviridae (74, 88).  
pUL71 possesses five sequence motifs that are necessary for its functions: an N-terminal 
palmitoylation site, N-terminal tyrosine-based trafficking motif, a leucine zipper-like motif, C-
terminal tetra-lysine motif, and Vps4-interacting motif.  The palmitoylation site is conserved 
across pUL71 homologs and is important for the localization of pUL71 to the cVAC, proper cVAC 
formation, and pUL71 stability.  The tyrosine-based trafficking motif consists of four amino acids 
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in the following configuration: YXX (X stands for any amino acid; stands for an amino acid with 
a bulky hydrophobic side chain). The tyrosine-based trafficking motif is also conserved across 
pUL71 homologs and important for the localization of pUL71 to the cVAC, proper cVAC 
formation, as well as cell-to-cell spread, secondary envelopment, and virion egress.  The leuzine 
zipper-like motif is important for proper cVAC formation.  The C-terminal tetra-lysine motif is 
important for secondary envelopment (32, 62, 87).  The importance of the Vps4-interacting motif 
is unknown (38). 
Localization of pUL71.  As a tegument protein, pUL71 is present in virions and dense 
bodies.  Within these particles pUL71 makes up a very small fraction of the total amount of protein 
present, around 0.1%.  Thus, at the beginning of an infection there is very little pUL71 present 
(102).  Being a beta gene product, expression of pUL71 ramps up later in infection.  At 120 hours 
post infection, the majority of pUL71 is present within the cVAC, localized at Golgi and trans-
Golgi network (TGN) membranes (38, 87, 88).   
Roles of pUL71 in HCMV infection.  pUL71 is involved in virion egress, cVAC 
formation, cell-to-cell spread, and virion maturation.  In one set of pUL71-knockout experiments 
the virus failed to grow indicating that pUL71 is essential for virus replication (35).  In another set 
of pUL71-knockout and pUL71 mutant virus experiments, intracellular and extracellular virus 
output decreases between 10 and 10,000-fold.  In addition there are decreases in cVAC formation, 
plaque sizes indicative of reduced cell-to-cell spread, and secondary envelopment, hampering 
virion maturation (88, 104, 110). 
Roles of pUL103 and pUL71 in HCMV infection.  In dual pUL71/pUL103-knockout 
experiments, extracellular viral titers and plaque sizes were reduced compared to the wild type 
virus.  However, there were no differences in these biological endpoints between the dual 
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pUL71/pUL103 knockout virus and the single pUL71- and pUL103-knockout viruses.  This 
suggests that pUL71 and pUL103 work together as a complex, within the same pathway or have 
redundant functions during HCMV infection.  In other studies, pUL71 and pUL103 were shown 
to interact outside the context of and during infection, evidence that further supports the two 
proteins forming a complex (14, 38, 72)   
Protein interaction partners of pUL71.  Studies have shown that pUL71 interacts with 
the ESCRT protein Vps4 during and outside the context of HCMV infection (38).  Studies from 
the Pellett and von Einem laboratories have shown that pUL71 interacts with pUL103 (38, 72). 
Characteristics of HSV pUL7 and pUL51 
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of HSV-1 pUL7.  The UL7 gene is located in the unique long region of the genome.  UL7 is a late 
gene, meaning it requires the expression of the immediate early and early genes for it to be 
transcribed and translated.  The UL7 gene product pUL7 is a small (296 aa, ~32.56 kDa), 
conserved tegument protein, with homologs in all viruses within the Herpesviridae (74, 79).  As 
mentioned above, the N termini of pUL7 homologs are more conserved than their C termini (Fig. 
1-7) and they contain a conserved herpesvirus domain (Fig. 1-8) with the sequence G-F-x(8)-E-D-
x-V-x(12)-R (71).   
Localization of pUL7.  pUL7 associates with capsids and is present in virions (71, 80).  
Being a gamma gene product, expression of pUL7 ramps up later in infection.  At 12 hours post 
infection, the majority of pUL7 is present in the cytoplasm in the vicinity of the TGN, with some 
in the nucleus (14, 71).  
Roles of pUL7 in HSV infection.  pUL7 is important for virion egress, cell-to-cell spread, 
secondary envelopment, stabilization of pUL51, and maintenance of focal adhesions.  When UL7 
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deletion mutant viruses are constructed, viral titers decrease 10-1,000-fold (3, 98).  There are also 
decreases in the numbers of cytoplasmic enveloped capsids, indicating defects with secondary 
envelopment.  When pUL7 is deleted, pUL51 expression decreases substantially compared to wild 
type.  In addition, in the absence of pUL7 focal adhesions failed to form, which seemed to correlate 
with changes in cell morphology and attachment.  Focal adhesions are contact sites between the 
extracellular matrix and the cytoplasm.  They are complex and dynamic structures that play roles 
in regulating cellular processes in response to extracellular stimuli and cell attachment and 
movement (3).  These structures also seem to be unique to alphaherpesviruses, as they are not 
present in the human beta- and gammaherpesviruses (14).   
Protein interaction partners of pUL7.  Several studies have shown that pUL7 interacts 
with pUL51 (3, 14, 80).  One study showed that pUL7 interacts with the adenine nucleotide 
translocator 2 (ANT 2) (98).  Another study, which developed a platform for identifying novel 
protein interactions between HSV-1 proteins, identified several tegument (pUL55, pUL14, 
pUL16) and an envelope (pUL45) proteins as potential interaction partners of pUL7 (7).   
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of HSV-1 pUL51.  The UL51 gene is located in the unique long region of the genome.  UL51 is a 
late gene, meaning it requires the expression of the immediate early and early genes for it to be 
transcribed and translated.  The UL51 gene product pUL51 is a small (244 aa, ~26.84 kDa), 
conserved tegument protein, with homologs in all viruses within the Herpesviridae (34, 74, 79).  
The N termini of pUL51 homologs are more conserved than their C termini and they contain a 
conserved N-terminal cysteine residue (palmitoylation site) and tyrosine-based trafficking motif 
(YXX) (80, 81). 
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Localization of pUL51.  pUL51 is present in virions and dense bodies.  Being a gamma 
gene product, expression of pUL51 ramps up later in infection.  Between 6 and 24-hours post 
infection, the majority of pUL51 is present in the cytoplasm, where it colocalizes with several 
Golgi marker proteins such as Golgi-58K, GM130, and COP.  The cysteine at position 9, the 
palmitoylation site, is important for the translocation of pUL51 to Golgi membranes and other 
membranous structures within the cell (14, 70, 79).  
Roles of pUL51 in HSV infection.  pUL51 is important for virion egress, cell-to-cell 
spread, secondary envelopment, stabilization and localization of pUL7, maintenance of focal 
adhesions, and formation of viral protein dense areas in neuronal cells.  When UL51 deletion 
mutant viruses are constructed, viral titers decrease ~ 10-300-fold.  Plaque sizes also decreased by 
~4.5-100-fold, indicating defects in cell-to-cell spread.  The tyrosine at position number 19, the 
leading residue of the conserved tyrosine-based trafficking motif, is necessary and sufficient for 
cell-to-cell spread in certain cell types.  In addition, lack pUL51 leads to decreases in the numbers 
of cytoplasmic enveloped capsids, indicating defects with secondary envelopment.  When pUL51 
is deleted, pUL7 expression decreases below the threshold of detection and is inefficiently 
translocated into virions.  In addition, in the absence of pUL51 focal adhesions failed to form, 
which seemed to correlate with changes in cell morphology and attachment.  Focal adhesions are 
contact sites between the extracellular matrix and the cytoplasm.  They are complex and dynamic 
structures that play roles in regulating cellular processes in response to extracellular stimuli and 
cell attachment and movement.  These structures also seem to be unique to alphaherpesviruses, as 
they are not present in the human beta- and gammaherpesviruses (3, 80, 81).  Mutation of pUL51 
tyrosine 19, as mentioned above, leads to loss of single areas of high viral protein concentration in 
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cancerous neuronal cells (103).  These structures are reminiscent of the cVACs present in HCMV-
infected cells, suggesting this maybe a common mechanism shared between the viruses.     
Roles of pUL7 and pUL51 in HSV infection.  In dual pUL7/pUL51-knockout 
experiments, extracellular viral titers and plaque sizes were reduced compared to the wild type 
virus.  However, there were no differences in these biological endpoints between the dual 
pUL7/pUL51-knockout virus and the single pUL7- and pUL51-knockout viruses.  This suggests 
that pUL7 and pUL51 work together as a complex within the same pathway and/or have redundant 
functions during HCMV infection.  Outside of and during the context of infection, pUL7 and 
pUL51 have been shown to interact with each other, solidifying the fact that they do form a 
complex (3, 14).  
Protein interaction partners of pUL51.  Several studies have shown that pUL51 interacts 
with pUL7 (3, 14, 80).  One study showed that pUL51 may also interact with itself and pUL35, 
the small capsomere-interacting protein (SCP).  The SCP decorates the outer layer of the hexons 
of the capsid, seemingly as a bridge between the capsid and tegument (7, 74, 79, 111).  
Characteristics of EBV BBRF2 and BSRF1 
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of BBRF2.  The BBRF2 gene is located in the unique long region of the genome (56).  BBRF2 is 
a late gene, meaning it requires the expression of the immediate early and early genes for it to be 
transcribed and translated.  The BBRF2 gene product BBRF2 is a small (278 aa, ~30.58 kDa), 
conserved tegument protein, with homologs in all viruses within the Herpesviridae (56, 60, 66, 
74).  As mentioned above, the N termini of BBRF2 homologs are more conserved than their C 
termini (Fig. 1-7) and they contain a conserved herpesvirus domain (Fig. 1-8) with the sequence 
G-F-x(8)-E-D-x-V-x(12)-R (71).   
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Localization of BBRF2.  BBRF2 is present in very low abundance in virions (47).  Thus, 
at the beginning of an infection there is very little BBRF2 present.  Being a gamma gene product, 
expression of BBRF2 ramps up later in infection.  Outside the context of infection, BBRF2 
localizes to the nucleus and juxtanuclear regions in the cytoplasm in a punctate pattern.  In the 
presence of its binding partner BSRF1, BBRF2 localizes only to the cytoplasm, in the vicinity of 
Golgi, in transfected cells (60, 108). 
Roles of BBRF2 in EBV infection.  BBRF2 is important for cell-to-cell spread and 
stabilization of BSRF1.  When BBRF2-knockout and deletion mutant viruses were constructed, 
permissive cells infected, supernatant collected, and new permissive cells infected with collected 
supernatant, the number of cells infected is less than that for the wild type virus. under the exact 
same conditions.  This suggests a defect in infectivity in the absence of BBRF2.  In the absence of 
BBRF2, BSRF1 protein levels decrease.  Given that BSRF1 is able to be ubiquitinated and its 
degradation is inhibited in the presence of MG132 (proteasome inhibitor), BBRF2 may protect 
BSRF1 from ubiquitination and subsequent degradation by the proteasome.  (60).   
Protein interaction partners of BBRF2.  Two studies have shown that BBRF2 interacts 
with BSRF1outside the context of and during infection.  BBRF2 has also been shown to interact 
with BGLF2, homolog of HSV-1 pUL16.  BGLF2 is a tegument protein important for virion 
maturation, egress, and virus infectivity (60, 108).  BBRF2 has also been shown to interact with 
several host proteins: C1orf50, CEP76, GOLGA2, OPTN, PNMA1, PTBP1, RINT1, TFCP2, and 
TTC12 (82). 
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of BSRF1.  The BSRF1 gene is located in the unique long region of the genome (56).  BSRF1 is a 
late gene, meaning it requires the expression of the immediate early and early genes for it to be 
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transcribed and translated (61, 66, 74).  The BSRF1 gene product BSRF1 is a small (218 aa, ~23.98 
kDa), conserved tegument protein, with homologs in all viruses within the Herpesviridae (47, 66, 
74).  The N termini of BSRF1 homologs are more conserved than their C termini and they contain 
a conserved N-terminal cysteine residue (palmitoylation site) and tyrosine-based trafficking motif 
(YXX) (80, 81) 
Localization of BSRF1.  BSRF1 is present in low abundance in virions (47).  Thus, at the 
beginning of an infection there is very little BSRF1 present.  Being a gamma gene product, 
expression of BSRF1 ramps up later in infection.  During infection, BSRF1 localizes to the 
cytoplasm, in the vicinity of Golgi membranes (108). 
Roles of BSRF1 in EBV infection.  BSRF1 is important for cell-to-cell spread in the 
marmoset B cell line B95-8.  In the presence of siRNAs against the BSRF1 gene, new virions 
produced under these conditions fail to infect as many cells as virions produced in the presence of 
a control siRNA.  These defective virions also contain less viral DNA than virions produced under 
the control condition (108).   
Protein interaction partners of BSRF1.  Two studies have shown that BSRF1 interacts 
with BBRF2 outside the context of and during infection (60, 108).  BSRF1 has also been shown 
to interact with BGLF3.5 (homolog of HSV1 UL14, encapsidation chaperone protein (ECP)) and 
BALF1 (one of two vBcl2s) (74, 108).  BSRF1 has been shown to interact with several cellular 
proteins: S100A6, SLC16A3, TBXAS1, and ZDHHC17 (82). 
Characteristics of KSHV ORF42 and ORF55 
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of ORF42.  The ORF42 gene is located in the central unique region of the genome (25).  ORF42 
is a late gene, meaning it requires the expression of the immediate early and early genes for it to 
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be transcribed and translated.  The ORF42 gene product ORF42 is a small (278 aa, ~30.58 kDa), 
conserved tegument protein, with homologs in all viruses within the Herpesviridae (13, 66, 74).  
As mentioned above, the N termini of ORF42 homologs are more conserved than their C termini 
(Fig. 1-7) and they contain a conserved herpesvirus domain (Fig. 1-8) with the sequence G-F-x(8)-
E-D-x-V-x(12)-R (71).   
Abundance and localization of ORF42.  ORF42 is present in virions.  Being a gamma 
gene product, expression of ORF42 ramps up later in infection.  At 96 hours post infection, the 
majority of ORF42 is present in the cytoplasm (13). 
Roles of ORF42 in KSHV infection.  ORF42 is important for virion egress and late 
protein expression.  When ORF42 deletion mutant viruses are constructed, viral titers decrease 10-
100-fold.  In addition, in the absence of full-length ORF42, protein levels of several early and late 
proteins decreased.  Further studies indicated that global synthesis of new proteins was decreased 
in the absence of full-length ORF42 (13).   
Protein interaction partners of ORF42.  Several studies have shown that ORF42 
interacts with ORF55 outside the context of infection (14, 60)  In another study ORF42 is predicted 
to interact with the protein NME2 (29).   
Genome information, expression kinetics, conservation, and sequence motifs/domains 
of ORF55.  The ORF55 gene is located in the central unique region of the genome (101).  ORF55 
is predicted to be an early or late gene based on the expression kinetics of its homologs in HCMV 
(pUL71, early gene), HSV-1 (pUL51, late gene), and EBV (BSRF1, late gene).  The ORF55 gene 
product ORF55 is a small (227 aa, ~24.97 kDa), conserved tegument protein, with homologs in all 
viruses within the Herpesviridae (66, 74).  The N termini of ORF55 homologs are more conserved 
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than their C termini and they contain a conserved N-terminal cysteine residue (palmitoylation site) 
and tyrosine-based trafficking motif (YXX) (80, 81). 
Localization of ORF55.  ORF55 is present in virions (52).  Outside the context of 
infection, ORF55 has been shown to accumulate almost exclusively in the cytoplasm, colocalizing 
with Golgi membranes (14, 86).  During infection, ORF55 primarily localizes to the cytoplasm, 
with little protein present in the nucleus (52). 
Roles of ORF55 in KSHV infection.  ORF55 is important for cell-to-cell spread and virion 
assembly.  When permissive cells are incubated with a vBcl2 peptide that inhibits the interaction 
between ORF55 and vBcl2, lytic infection induced, supernatant collected, and new permissive 
cells infected with virions from supernatant, the number of cells infected is less than the number 
produced in the presence of the control peptide.  Also, when the ORF55/vBcl2 interaction is 
disrupted less intracellular virions are produced (52).   
Protein interaction partners of ORF55.  Studies have shown that ORF55 interacts with 
ORF42 outside the context of infection (14, 60)  In other experiments ORF55 has been shown to 
interact with the cellular proteins GOSR1 and STING (component of the cGAS/STING DNA 
sensing pathway) and the viral protein vBcl2 (ORF16) (29, 40, 52). 
This work 
Summary.  Data from the Pellett laboratory supports the hypothesis that pUL103 has 
multiple roles throughout HCMV lytic infection and its various activities depend upon its structural 
domains and presence at specific times during infection.  My objectives were to determine the 
structure-function relationship of pUL103 in HCMV infection and to identify the temporal window 
when pUL103 was required for cVAC biogenesis and maintenance for focused mechanistic 
studies.  From my structural studies, I found that the predicted structure of pUL103 most closely 
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resembles that of the non-catalytic LIM domain of human terminal uridylyl transferase 4 (TUT4), 
a nucleotidyl transferase domain that lacks catalytic residues.  Based on its predicted structure, 
pUL103 may thus function to bind RNA species for catalysis.  This data provides the foundation 
for studies into whether pUL103 is capable of binding nucleic acids.  During my biological studies 
to determine the period when pUL103 is required for cVAC biogenesis and maintenance, I found 
that late in infection, pUL103 needs to be present by 72 hours for normal cVAC biogenesis to 
occur.  In addition, pUL103 needs to remain present longer than 84 hpi for the percentage of 
cVACs to be maintained during infection.  This data helps us in achieving our long-term goal of 






FIG 1-1 Diagram of a herpesvirus virion.  Illustration showing the four main components 
(envelope, tegument, capsid, DNA) of an infectious herpesvirus particle.  Image modified from 
that in reference (97). 
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FIG 1-2 General overview of the herpesvirus replication cycle.  Viral infection begins with 
attachment, followed by fusion of the cell membrane and viral envelope, entry of the capsid and 
tegument into the cytoplasm (steps 1-4).  The capsid is trafficked to the nuclear pore and the 
DNA deposited into the nucleus (steps 5a-7).  The viral cascade of gene expression begins with 
transcription and translation of the immediate early genes, followed by the early and late genes 
(steps 8-18).  Capsids are assembled in the nucleus, acquire their inner teguments, undergo 
primary envelopment within the inner nuclear membrane, and are translocated into the 
perinuclear space (steps 18-19).  The capsids undergo de-envelopment and are transported into 
the cytoplasm by fusion of their envelope with the outer nuclear membrane (step 20).  In the 
cytoplasm, the capsids acquire their outer tegument, undergo secondary envelopment, and are 
translocated to the cell surface for egress (steps 21-24). Image is from reference (39).   
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Table 1-2 Betaherpesvirus genes conserved across the Herpesviridae 
Function (gene name) HCMV 
HHV-6A, HHV-6B, 
and HHV-7 HSV 
Gene regulation    
Multifunctional regulator of expression (MRE) UL69 U42 UL54 
Nucleotide metabolism 
Ribonucleotide reductase, large subunit (RR1) UL45 U28 UL39 
Uracil-DNA glycosylase (UNG) UL114 U81 UL2 
Deoxyuridine triphosphatase (dUTPASE) UL72 U45 UL50 
DNA replication 
Helicase/primase complex 
   ATPase subunit (HP1) UL105 U77 UL5 
   RNA pol subunit (HP2) UL70 U43 UL52 
   subunit C (HP3) UL102 U74 UL8 
DNA polymerase (POL) UL54 U38 UL30 
ssDNA-binding protein (SSB) UL57 U41 UL29 
DNA polymerase processivity subunit (PPS) UL44 U27 UL42 
Virion 
Nonstructural; roles in virion maturation 
Alkaline exonuclease (NUC) UL98 U70 UL12 
Capsid transport nuclear protein (CTNP) UL52 U36 UL32 
Terminase-binding protein (TERbp) UL51 U35 UL33 
Terminase (TER)  
   TER ATPase subunit (TER1) UL89 U66 UL15 
   TER DNA recognition subunit (TER2) UL56 U40 UL28 
Assembly protease (PR) UL80a U53 UL26 
Assembly protein precursor (pAP) UL80.5 U53a UL26.5 
Capsid nuclear egress complex 
   Nuclear egress membrane protein (NEMP) UL50 U34 UL34 
   Nuclear egress lamina protein (NELP) UL53 U37 UL31 
Capsid 
Major capsid protein (pentons and hexons; MCP) UL86 U57 UL19 
Portal protein (PORT) UL104 U76 UL6 
Portal capping protein (PCP) UL77 U50 UL25 
Capsid triplex 
   Monomer (TRI1) UL46 U29 UL38 
   Dimer (TRI2) UL85 U56 UL18 
   Small capsid protein (SCP) at hexon tips UL48.5 U32 UL35 
Tegument 
 
Capsid transport tegument protein (CTTP) UL93 U64 UL17 
Cytoplasmic egress facilitator 2 (CEF2) UL87 U58 UL21 
Cell-to-cell fusion inhibitor UL76 U49 UL24 
Large tegument protein (LTP) UL48 U31 UL36 
LTP-binding protein (LTPbp) UL47 U30 UL37 
Encapsidation and egress protein (EEP) UL103 U75 UL7 
Myristoylated/palmitoylated cytoplasmic egress 
tegument protein (CETP) 
UL99 U71 UL11 
Virion protein kinase (VPK) UL97 U69 UL13 
Encapsidation chaperone protein (ECP) UL95 U67 UL14 
CETP-binding protein (CETPbp) UL94 U65 UL16 
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Cytoplasmic egress facilitator 1 (CEF1) UL71 U44 UL51 
Envelope 
Glycoprotein B (gB) UL55 U39 UL27 
Glycoprotein H (gH) UL75 U48 UL22 
Glycoprotein L (gL) UL115 U82 UL1 
Glycoprotein M (gM) UL100 U72 UL10 
Glycoprotein N (gN) UL73 U46 UL49.5 
Table from reference (20), adapted from information in references (74) and (68) and 






























FIG 1-3 Three- dimensional reconstructions from cryoelectron microscopy images of 
herpes simplex virus type 1 pentons and hexons. (A) Top and side views of penton. (B) Top 
and side views of hexon. Images are representative of the analogous structures of HCMV.  Image 











FIG 1-4 Three- dimensional reconstructions of cryoelectron microscopy images of HCMV 
nuclear capsids. (A) View along an icosahedral five-fold symmetry axis. (B) View along an 






FIG 1-5 Protein-protein interactions within the tegument. The schematic represents a mature 
enveloped virion and the types of protein-protein interactions proven or predicted to occur during 





FIG 1-6 Immunofluorescence assay (IFA) image of the cVAC in an HCMV-infected cell. 
IFA of a confocal 3D reconstruction of a human lung fibroblast infected with HCMV showing a 
cVAC: a Golgi ring surrounding primarily early and recycling endosomes. Image is from 
reference (27). 
DAPIGM130 (Golgi) EEA1 (EE/RE) HCMV(AD169) in HLF cells 5 dpiGrid spacing = 3.30688 µm
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Table 1-3 Characteristics of HCMV pUL103, HCMV pUL71 and their homologs HSV-1 pUL7, 
HSV-1 pUL51, EBV BBRF2, BSRF1, KSHV ORF42, and KSHV ORF55 
 
+ indicates the protein has the given property.  Blank fields indicate a lack of information on the 
given property for that protein.  If Information in the table was obtained from the following 
references: HCMV pUL103: (1, 26, 35, 38, 64, 72, 74, 102); HCMV pUL71: (3, 38, 74, 87, 88, 
102, 104, 110); HSV-1 pUL7: (3, 14, 71, 74, 79, 80); HSV-1 pUL51: (3, 14, 34, 70, 74, 79-81, 
103) (Reference (103) shows pUL51 is involved in formation of single, viral protein dense areas 
similar to HCMV cVACs);EBV BBRF2: (47, 56, 60, 66, 108); EBV BSRF1: (47, 61, 66, 74, 







FIG 1-7 FIG 1-7 The N terminus (residues 1-125) of pUL103 is more conserved than the C 
terminus (residues 126-249).  Similarity plot of pUL103 and 59 of its homologs from across the 
three subfamilies of the Herpesviridae with a sliding window of 5, generously provided by Dr. 
Richard Roller.  y-axis scale: 0 (no similarity across residues) to 8 (identical residues).  The 
green and red lines represent the average conservation scores of the N and C termini, 
respectively.  The conserved herpesvirus domain consists of residues 65-91.  Positions that have 





































FIG 1-8 Diagram of the pUL103 amino acid sequence with confirmed and putative sequence 
domains.  There are several literature sources documenting the conserved herpesvirus domain in 
pUL103 homologs.  The putative DEAD/DEAH box and the late domains were recently identified 
in the pUL103 amino acid sequence by our laboratory.  Further studies are needed to fully validate 




CHAPTER 2: PROTEIN SEQUENCE ANALYSIS AND STRUCTURAL PREDICTION 
OF PUL103 HOMOLOGS 
Introduction 
HCMV has the largest genome of the nine human herpesviruses (33, 74) Its genome 
consists of 236 kb that encodes a multitude of gene products; these include at least 167 proteins, 
four large, noncoding RNAs, two oriLyt RNAs, and at least 23 microRNAs.  HCMV is a master 
manipulator.  This large genome and its corresponding products ensure that HCMV has everything 
necessary to prepare the intracellular environment for efficient production of new virions (20, 64).  
Preparing a cell to assemble and produce new virus particles requires a great deal of coordination 
by the virus’s tegument.   
The tegument is a layer of proteins and RNA that lies beneath the viral envelope and is 
present only in herpesviruses.  Though it appears to lack a well-defined structure, there is some 
semblance of organization to this virion component (20).  After the viral envelope fuses with the 
cellular membrane or an intracellular membrane after endocytosis, the tegument is immediately 
deposited into the cytoplasm where the components begin modulating the cellular environment to 
facilitate virion production (94).  There are at least 38 different tegument proteins, present in 
various quantities, within HCMV virions.  Tegument proteins are important for many processes 
throughout infection.  Some of these proteins have roles in the virus life cycle such as trafficking 
of the capsid to and release of the viral DNA into the nucleus, transcriptional regulation, or virion 
assembly.  Other tegument proteins have roles in modulating cellular processes and pathways.  
This includes but is not limited to the evasion of the cell’s immune response, inactivation of host 
cell transcriptional repression mechanisms, alteration of the cell cycle, manipulation of intrinsic 
host defenses, cell death and signaling pathways (64).  Many, if not most tegument proteins, 
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perform multiple, distinct functions.  This is true for the tegument protein pUL103 that is the focus 
of my work. 
pUL103 is a conserved HCMV tegument protein that has many roles throughout HCMV 
infection (26, 72, 74).  In knockout experiments, pUL103 has been shown to be important for 
production of extracellular virus, with viral titers decreasing between 100 – 10,000 fold in its 
absence (35, 110).  In experiments where pUL103 protein levels were able to be regulated, 
knockdown of pUL103 resulted in decreases in cVAC biogenesis, cell-to-cell spread, and 
secondary envelopment (26).  The homologs of pUL103 in other herpesviruses have also been 
examined for their roles in virus infection.  HSV-1 pUL7 plays roles in virion egress, cell-to-cell 
spread, secondary envelopment, stabilization of pUL51, and maintenance of focal adhesions (3, 
98).  EBV BBRF2 is needed for progeny virus infectivity and stabilization of BSRF1 (60).  KSHV 
ORF 42 is necessary virion egress and late protein expression (13).  Though several of the activities 
of these proteins are known, the exact mechanisms of how they perform their functions are 
unknown, along with their structures.   
To address these unknowns, I analyzed the protein sequences of pUL103 and its homologs 
using the Protein BLAST through NCBI, a multiple sequence alignment, and the online server I-
TASSER.  The Protein BLAST is an alignment tool that can perform pairwise alignments between 
pairs of amino acid sequences and identify other proteins, potential homologs, with similar 
sequences to a query sequence (4).  A multiple sequence alignment is an alignment of numerous 
sequences by similarity of their nucleotides or amino acids.  Of the several programs that can be 
used to produce multiple sequence alignments, e.g., MUSCLE, MAFFT, CLUSTALW, T-Coffee, 
I used MUSCLE.  From such analyses, conserved amino acids, motifs, regions, etc., can be 
identified (36, 57).   
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I-TASSER is an online server, created by the Zhang laboratory at the University of 
Michigan-Ann Arbor, that produces structure and function predictions from an amino acid 
sequence. The I-TASSER algorithm is quite complex but involves (1) retrieving protein structures 
from the protein data bank (PDB) and using them as templates for the predicted folds of the protein 
of interest, (2) complete models are built and undergo refinement, (3) the predicted structures 
undergo more refinement and structures with the least potential energies are identified, and (4) the 
final predicted structure is compared to crystallized structures of proteins to identify structural 
analogs and hints of possible functions (109).  There are benefits and downsides to structural 
predictions.  The benefits include having access to a structure, the ability to design and execute 
experiments in silico, and to obtain real results that can help guide and inform future experiments.  
The downsides include not knowing whether the predicted structure is the actual structure until the 
protein is crystallized and possibly wasting time generating erroneous data.  I-TASSER addresses 
these downsides by participating in the Critical Assessment of Techniques for Protein Structure 
Prediction (CASP).  CASP is a community-wide experiment that has been held every two years 
since 1994.  This experiment tests the state-of-the-art of protein structure prediction software from 
investigators internationally.  The experiment, in the form of a competition, is blinded so the 
structures of proteins to be tested are unknown to the participants.  I-TASSER has participated in 
the CASP experiments since 2006.  During that time, it has been the highest ranked server for 
automated protein structure prediction.  It was only recently knocked into the number two position 
by another server produced by the Zhang lab, QUARK at CASP 13 in 2018.  (51, 92, 109).   
Methodology 
Protein BLAST.  The HCMV pUL103, HSV-1 pUL7, and EBV BBRF2 protein sequences 
were used as input into the Protein BLAST tool to perform pairwise alignments (19).  
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I-TASSER (Iterative Threading ASSEmbly Refinement).  An on-line server that uses 
the I-TASSER algorithm to produce protein structure and function predictions from amino acid 
sequences (109).  The amino acid sequences of pUL103 and its well-studied homologs pUL7 and 
BBRF2 were provided to the I-TASSER server and output, consisting of but not limited to 
predicted structures and structural analogs, was analyzed. 
MegAlign Pro by DNAstar.  A computer software program that performs multiple 
alignments of large DNA, RNA, and protein sequences and offers four alignment methods: 
MUSCLE, Mauve, MAFFT, and Clustal Omega.  MUSCLE, using default parameters, was used 
to align the protein sequences of pUL103 and its homologs (36). 
Nanoscale Molecular Dynamics and Visual Molecular Dynamics (NAMD/VMD).  
Computer software that simulates the dynamic molecular movements of large biomolecular 
systems.  This allows for analysis of native, complexed, predicted, or known protein structures. 
Phylogeny.fr. A simple to use web service dedicated to reconstructing and analyzing 
phylogenetic relationships between molecular sequences.  The program runs and connects various 
bioinformatics programs to reconstruct a robust phylogenetic tree from a set of sequences (30, 31). 
PRESTO (a Phylogenetic tReE viSualisaTiOn). An online phylogenetic tree 
visualization tool provided by the ATGC Montpellier Bioinformatics Platform.  This platform 
provides several tools for conducting analyses in the following areas: phylogenetics, molecular 
evolution, genome dynamics, comparative and functional genomics, and transcriptomics. 
PyMOL.  A computer software program that allows for the visualization and manipulation 
of small molecules and biological macromolecules such as proteins (6).  PyMOL was used to 
visualize and align the predicted structures of pUL103 and its homologs as well as crystalized 
structures of proteins. 
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Similarity plot.  A similarity plot of pUL103 and homologs was created by obtaining 
sequences from the Protein BLAST search of the HCMV pUL103 protein sequence.  The 
sequences were aligned using MUSCLE, with default parameters, from the European Molecular 
Biology Laboratory-European Bioinformatics Institute (EMBL-EBI).  Once aligned, the 
sequences were imported into Jalview, a sequence editor, where conservation scores at all the 
amino acid positions were observed.  The conservation score is measured as a numerical index 
reflecting the conservation of physical and chemical properties of amino acids within the 
alignment.  Identities score the highest followed by groups that contain substitutions to amino acids 
with similar properties.  The conservation scores were imported into Microsoft Excel and graphed 
(4, 19, 36, 54, 57). 
Results 
pUL103 and its homologs share limited sequence identities.  To determine how similar 
pUL103 homologs are, I performed pairwise alignments using the Protein BLAST tool through 
the National Center of Biotechnology Information (NCBI) on the protein sequences of HCMV 
pUL103, HSV-1 pUL7, and EBV BBRF2.  pUL103 homologs contain a conserved domain known 
as the conserved herpesvirus domain that is also present in the topoisomerase III of fission yeast.  
It is located in between residues 65 and 91 in pUL103, between residues 101 and 127 in HSV-1 
pUL7, and in between residues 74 and 100 in EBV BBRF2.  In all sequences, this domain is located 
closer to the amino terminus than the carboxyl terminus.  Using the Protein BLAST tool, I 
determined that pUL103 shares ~29% sequence identity with pUL7 and ~30% with BBRF2.  pUL7 
shares ~31% sequence identity with BBRF2 (Fig. 2-1 A-C).  The majority of the shared identities 
between all three sequences are located within close proximity to the conserved herpesvirus 
domain.  In addition, HCMV pUL103 and HCMV pUL7 share four amino acids within a stretch 
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of five residues near their carboxyl ends.  The residues are rich in prolines with a putative motif of 
LPxPP.  These proline-rich residues may be used to bind ESCRT machinery or SH3-domain 
containing proteins (2, 83).  BBRF2 shares several residues with pUL103 at its carboxyl end (Fig. 
2-1 A-B).  From their identities, it appears that these homologs are not closely related.  To better 
elucidate the homology of these sequences, I decided to perform a phylogenetic analysis of all the 
pUL103 homologs from the human herpesviruses as well as those from several animal 
cytomegaloviruses, a total of fourteen sequences (Fig. 2-2). 
Phylogenetic analysis reveals relationships amongst pUL103 homologs.  To better 
understand the ancestral relationships of the pUL103 homologs, I utilized bioinformatics software 
to produce a phylogenetic tree from their protein sequences (Fig. 2-3).  The tree showed homologs 
from viruses within the same subfamilies clustered together.  It also showed the branch lengths of 
homologs from closely related viruses human herpesviruses 6A and B and herpes simplex viruses 
1 and 2 as being zero or very short, respectively.  This information correlates with what is already 
known about the viruses.  The tree showed that the homologs from the alphaherpesviruses are 
more closely related to the homologs from the gammaherpesviruses; whereas gammaherpesviruses 
themselves are more closely related to betaherpesviruses.  This may be factual or the common 
ancestor for all three subfamilies goes back so far, the software had difficulty determining the 
proper branching points.  Within the betaherpesvirus homologs, those belonging to the 
roseoloviruses cluster together, those from the rodent cytomegaloviruses cluster together, and 
those from the primate cytomegaloviruses cluster together.  Within these clusters, the mouse 
pUL103 homolog is more closely related to the rat homolog than the one from GPCMV and 
pUL103 is more closely related to homolog pRh140 than the pUL103 homolog from CCMV.  This 
information helped to highlight how the pUL103 homologs are related.  After conducting a 
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phylogenetic analysis, I performed a sequence alignment of the homologs to look for conserved 
regions.  
MUSCLE alignments show areas of conservation across pUL103 homologs.  To 
identify conserved regions (motifs) and/or specific amino acids important for the function of 
pUL103, I aligned the protein sequences of the fourteen pUL103 homologs using MUSCLE 
(Multiple Sequence Comparison by Log-Expectation) (Fig. 2-4).  The alignment showed (a) 
conserved side chain chemistry of the residues throughout the length of the pUL103 sequence, (b) 
numerous positions with perfectly conserved residues within and across the subfamilies, (c) the 
largest concentration of perfectly conserved residues lies within the conserved herpesvirus domain, 
(d) potential conserved motifs near the amino and carboxyl termini of the cytomegaloviruses (Fig. 
2-5), (e) eight dileucine motifs present in the pUL103 sequence, and (f) the gamma herpesvirus 
subfamily has the most positions with perfectly conserved residues.  One piece of information we 
hoped to gain from the alignment is the identification of residues suitable for mutagenesis.  These 
would be residues that are conserved in two of the three herpesvirus subfamilies.  The majority of 
these residues are present in the conserved herpesvirus domain (65-G, 66-Y, 75-E, 76-D, 91-R).  
However, there are some residues outside of this domain that are also conserved and would be 
interesting to study (7-R, 11-E, 53-Y, 63-F, 96-K, 103-F, 106-C, 113-E, 170-P, 191-F, 192-F, 214-
D).  This alignment shows how similar HCMV pUL103 and its homologs are.  Prior to conducting 
my alignment, Dr. Richard Roller from the University of Iowa performed a MUSCLE alignment 
of pUL103 and 59 of its homologs and used their conservation scores to produce a similarity plot 
(Fig. 2-6).  A similarity plot shows residue similarity at each position along the length of the 
alignment.  This plot correlates with the information that is seen in my alignment; the peaks of the 
similarity plot align with the highly conserved residues I identified.  Using the similarity plot from 
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Dr. Roller and a sliding window of 5, I showed that the N terminus of pUL103 homologs is  more 
conserved than the C terminus.  I determined the average conservation score of the N terminus 
(residues 1-125) to be 3.8, and greater than that of the C terminus (residues 126-249), which had 
an average conservation score of 2.3 (Fig. 2-7).  After determining the extent of the similarity of 
these proteins through their sequences, I wanted to see how this information correlated with their 
structures.  
I-TASSER structure and function predictions of pUL103 homologs provide insight 
into the functions of these proteins.  When I began my analysis, there were no crystal structures 
of any of the pUL103 homologs.  Thus, to gain insight into the structures of these proteins, I 
utilized I-TASSER (Iterative Threading ASSEmbly Refinement), an online server for protein 
structure and function prediction.  Using I-TASSER, I produced predictions of the structures for 
HCMV pUL103, and its homologs HSV-1 pUL7 and EBV BBRF2 (Fig. 2-8 A-C).  The predicted 
structure of pUL103 is modular with a primarily unstructured amino terminus with some beta 
strands and a primarily alpha-helical carboxyl terminus with an unstructured tail.  The predicted 
structure of pUL7 resembles that of pUL103 and also contains an elongated, primarily alpha helical 
N terminal region.  The predicted structure of BBRF2 contains many alpha helices all throughout 
the structure and does not share the same shape common to the structures predicted for pUL103 
and pUL7.  However, the predicted secondary structures of all three homologs, also produced by 
I-TASSER, are similar (data not shown).  When the predicted structures of pUL103 and pUL7 are 
aligned using PyMOL, they align very well (Fig. 2-9 A).  When the predicted structures of pUL103 
and BBRF2 are aligned, there is hardly any overlap in the structures (Fig. 2-9 B).The differences 
between the predicted structures of pUL103, pUL7 and BBRF2 could be due to BBRF2 possibly 
having different or additional functions compared to those of pUL7 and pUL103, different tertiary 
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structures leading to similar functions, or the lack of appropriate proteins in the protein data bank 
for appropriate threading by I-TASSER. Having the predicted structure of pUL103 allowed me to 
conduct other analyses in addition to the structural alignments with its homologs.   
In collaboration with the Kovari laboratory, I conducted molecular dynamics simulations 
using Nanoscale Molecular Dynamics and Visual Molecular Dynamics (NAMD/VMD) of the 
predicted structure of pUL103.  This software simulates the dynamic molecular movements of 
large biomolecular systems, allowing for analysis of protein structures.  The results of the analyses, 
root mean square deviation (RMSD), help to determine areas of rigidity or flexibility within the 
structure (76).  These areas could be indicative of active sites, binding sites, catalytic sites, etc.  
Analysis of the predicted pUL103 structure showed that amino acids near the beginning of the 
conserved herpesvirus domain and those at the carboxyl terminal tail exhibit the most movement, 
as evidenced by their high RMSD values (red color in the heat map, high peaks on the graph).  All 
throughout the protein, there are regions of alternating movement (Fig. 2-10).  The most interesting 
sites to study based on these experiments are the very flexible regions at the beginning of the 
conserved herpesvirus domain and those at the C terminus.  The conserved herpesvirus domain is 
worthy of study because of its conservation and possible connection to nucleic acids.  We have 
previously shown that tags at the C terminus of pUL103 affect the ability of the virus to replicate 
(26).  This suggests that the C terminus of pUL103 is important for its function and the biology of 
the virus.  These could be sites for binding proteins, substrates, nucleic acids, etc. 
In addition to providing secondary and tertiary structure predictions, I-TASSER also 
identified ten proteins, whose structures have been crystallized, that are similar to the pUL103 
predicted structure.  These suggested structural analogs are nucleotidyl transferases (Fig. 2-11).  
Nucleotidyl transferases are proteins that bind RNA and do not require a template to execute their 
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polyadenylation, uridylation, and other enzymatic activities (59).  The top match for the predicted 
pUL103 structure (Fig. 2-12 A) was the catalytic domain of the human terminal uridylyl 
transferase 7 (TUT7) protein (Fig. 2-12 B).  I aligned the predicted pUL103 structure with the 
TUT7 protein (Fig. 2-12 C) and the other nine structural analogs (data not shown) and they all 
aligned well with the pUL103 predicted structure.  Given that the pUL103 predicted structure 
aligned well with the ten nucleotidyl transferases, I wanted to see if the pUL103 homologs shared 
similar protein chemistry with them.  Thus, I conducted another MUSCLE alignment with the 
protein sequences of the nucleotidyl transferases and those of HCMV pUL103, HSV-1 pUL7, and 
EBV BBRF2 (Fig. 2-13).  The alignment showed (a) numerous occurrences of shared protein 
chemistry between each of the herpesvirus homologs and at least half (five) of the nucleotidyl 
transferases, (b) the conserved herpesvirus domain has the greatest number of positions where all 
three pUL103 homologs share similar residue chemistry with the  nucleotidyl transferases, 
followed by alpha helix 5, and (c) some active site residues of the human TUT7 protein are 
conserved across the pUL103 homologs as well.  This suggests that the pUL103 homologs may 
be related to nucleic acid binding proteins. 
However, upon closer examination, I observed that the pUL103 predicted structure does 
not contain the catalytic aspartate residues of nucleotidyl transferases.  Thus, I proceeded to 
investigate whether proteins existed that resemble nucleotidyl transferases but lack catalytic 
activity.  In my search I came across the LIM domain of the human TUT4 protein (Fig. 2-14 B).  
This domain is a nucleotidyl transferase domain that is catalytically inactive; it lacks the catalytic 
aspartate residues.  It does not catalyze the polyadenylation, mono- or polyuridylation of RNA 
species.  It instead binds RNA substrates and positions them for processing by the catalytic domain 
(107).  When I aligned the TUT4 LIM domain with the predicted structure of pUL103 (Fig. 2-14 
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A), there was significant overlap between the structures (Fig. 2-14 C).  Based on their predicted 
structures, pUL103 and its homologs may function to bind RNA species for catalysis.  This data 
provides the foundation for studies into whether pUL103 is capable of binding nucleic acids.  
Structure of HSV-1 pUL7 solved.  The crystal structure of HSV-1 pUL7 was recently 
solved (Fig. 2-15 B).  This crystallized structure contains residues 11-234 and 253-296.  The N 
terminus consists of an equal mix of beta strands and alpha helices.  The C terminus primarily 
consists of alpha helices.  The investigators noted that the pUL7 structure has a novel fold not seen 
in other structures.  The predicted structure of pUL7 (Fig. 2-15 A) lacks the N terminal beta strands, 
but contains a C terminus with many alpha helices.  When the two structures are aligned, there is 
no obvious overlap, though they share similar secondary structures (Fig. 2-15 C).  The crystallized 
structure of pUL7 was produced while in the presence of its binding partner pUL51.  The predicted 
structure was produced in the absence of this binding partner; this could explain the differences in 
the two structures.  The binding partner may have caused pUL7 to adopt a different conformation 
that the prediction software could not account for.  It is also more than likely that the prediction is 
wrong.  The pUL7 structure contains a novel fold; structures with this fold did not exist in the 
protein data bank for the most accurate structural prediction to be made by the software. 
Discussion 
To fill gaps relating to the structure and function of HCMV pUL103 and its homologs, I 
analyzed their protein sequences and produced structural predictions.  One of the most interesting 
insights from doing this research is that more than one method was needed to explore the 
conservation of pUL103 and its homologs.  Using only sequence identities to study these proteins 
would lead to the conclusion that they are not very similar.  It is not until the sequence alignment 
is performed that relationships, outside of possessing the conserved herpesvirus domain, amongst 
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the proteins are visible.  The conserved amino acids and possible motifs identified by this work 
provide the foundation for the development of novel experiments investigating their role in the 
function of pUL103 and HCMV biology as a whole.  In addition, I also showed that the N terminus 
of pUL103 is more conserved than the C terminus.  I hypothesized this to mean that the N terminal 
domain is more important for pUL103 function than the C terminal domain.  However, given that 
each cytomegalovirus is species specific, it is possible that the C terminus contains species specific 
residues and explains the decrease in conservation in this area. 
Given that a protein’s structure can provide insight into its function, I sought to develop 
structural predictions of pUL103 and its homologs because theirs were not determined.  The 
pUL103 homolog predicted structures, the nucleotidyl transferase structural analogs, and the 
sequence alignment of both suggest that pUL103 and its homologs may interact with nucleic acids.  
This correlates with the presence of the conserved herpesvirus domain within the homologs.  Thus, 
these studies provide a logical pathway for the investigation of whether pUL013 and its homologs 
are capable of binding, modifying, etc. nucleic acids; however, these experiments were not tested 
in our lab.  The crystallized HSV-1 pUL7 structure revealed there were differences between it and 
the predicted pUL7 structure.  This could occur for several reasons: (a) the presence of the binding 
partner affects the conformation adopted by pUL7, (b) the reagents used to produce the crystals 
for X-ray crystallography may affect the conformations the protein adopts, (c) the protein structure 
produced in the crystals may not be what occurs naturally outside of the laboratory, or (d) the 
appropriate crystal structures did not exist for the most accurate structural prediction, and thus the 
structural prediction was wrong.  In addition, the methods of structure and function prediction are 
constantly being improved to increase their accuracy.  In the case of I-TASSER, the software is 
constantly being updated with new structures from the protein data bank, which help to improve 
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the threading and predictions.  The Zhang lab that created I-TASSER has also developed auxiliary 
programs to work with I-TASSER to create improved structural predictions.  With the pUL7 
structure solved, some next steps would be to: (a) extract the secondary structure from the 
crystallized protein and compare with the a new prediction, (b) perform another prediction with 
the updated I-TASSER software and compare to the crystallized structure, and (c) use protein 
structure search engines to identify any proteins with solved structures similar to that of pUL7, 
using their annotations, if any, to design experiments to investigate pUL103 and its homologs for 






FIG 2-1 Human herpesvirus pUL103 homologs share limited sequence identities.  NCBI 
BLAST analysis of HCMV pUL103, HSV-1 pUL7, EBV BBRF2, and VoHV1 ORF42.  (A) 
Alignment information for HCMV pUL103 and HSV-1 pUL7.  (B) Alignment information for 


















































FIG 2-2 List of pUL103 homologs used for analysis.  The 14 pUL103 homologs that were 
analyzed using several bioinformatics methods. 
  





Chimp cytomegalovirus  (CCMV) pUL103 NP_612734.1
Rhesus cytomegalovirus  (RhCMV) pRh140 YP_068231.1
Guinea pig cytomegalovirus  (GPCMV) pGP103 YP_007417869.1
Mouse cytomegalovirus  (MCMV) pM103 YP_214103.1
Rat cytomegalovirus  (RCMV) pE103 YP_007016499.1
Human herpesvirus 6A (HHV6A)
Roseolovirus
pU75 NP_042968.1
Human herpesvirus 6B (HHV6B) pU75 NP_050254.1
Human herpesvirus 7 (HHV7) pU75 YP_073815.1
Alphaherpesviruses
Herpes simplex virus type 1 (HSV1) Simplexvirus pUL7 YP_009137081.1
Herpes simplex virus type 2 (HSV2) pUL7 YP_009137158.1
Varicella zoster virus (VZV) Varicellovirus ORF53 NP_040175.1
Gammaherpesviruses
Epstein-barr virus (EBV) Lymphocryptovirus BBRF2 YP_001129477.1





FIG 2-3 Phylogenetic analysis reveals relationships among pUL103 homologs.  Phylogenetic 
tree of pUL103 and homologs produced using Phylogeny.fr (default settings using “One-Click” 



























FIG 2-4 MUSCLE Alignment shows conserved protein chemistry across the 14 pUL103 
homologs. DNASTAR MUSCLE alignment (using default settings) of the HCMV pUL103 
























    













    













    































    








    









    










    





    













































































































































































































































FIG 2-5 MUSCLE Alignment shows potentially conserved cytomegalovirus motifs.  Red 
squares surround the putative amino and carboxyl terminal motifs of the cytomegaloviruses 























    













    













    































    








    









    










    





    













































































































































































































































FIG 2-6 MUSCLE alignment produced in this study correlates with similarity plot from 
Dr. Richard Roller.  Similarity plot of pUL103 and 59 of its homologs from across the three 
subfamilies of the Herpesviridae, generously provided by Dr. Richard Roller.  y-axis scale: 0 (no 
similarity across residues) to 12 (identical residues).  The conserved herpesvirus domain consists 
of residues 65-91; conserved residues within the conserved domain are marked with a black 
arrow , residues outside of this domain are marked with an *.  Positions that have conservation 
















Ruler 1 1 10 20 30 40 50 60 70 80 90
Consensus - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f
HCMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L
Chimp CMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V
Rhesus CMV prh140 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V
Guinea pig CMV pGP103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F
Mouse CMV pM103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F
Rat CMV pE103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L
HHV6A pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F
HHV6B pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F
HHV7 pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F
HSV1 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F
HSV2 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F
VZV pORF53 M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V
EBV pBBRF2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - -
KSHV pORF42 - - - - - - - - - - - - - - - - - - - - - - - - - - M S L E R A L A R L T G V P M S T H A P K T R E S E E A C P V Y P H P V V P R L V L E V H - - - - R K N N A L V G S N T P K M - S V M G - - - - - -
Sequence Logo M Q R I R P Y W I K F E Q T G G A G M A D G M S G IM NMA SIDA LAP SET RPIA LDA LGD CAE SRG VTSL TA MIGA VTDA SPNI MGL SLK HTQM TRKHA QLSIA ELAP EAKG TSMKGD TQRL REDASK VGASLE SPFEVL TSDE MDVAT QPLICSA KPED IDAMGV YLISMF RPLDESN SRQMHATNI PQ TSVAL VTSIHLM LIPV R NMFATLG MIAV MCL KE LAV NIRH EQNKT HIVD EF SGT SKGEADR QEDLHKR YHGQKCN TNIAPV AMISR VCIFL LKIAVTM VTSGERNA SNLHTP RDQPNES TLIV TMIAPLV KERNSD MLVFI Y RNSDT LAV VTMARKSG PNGD RGEA RHCGD KDGQR VMEIL TLRW LVF RQLVH4.302.2
Ruler 2 1 10 20 30 40 50 60 70 80 90
Ruler 1 110 120 130 140 150 160 170 180 190
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f h t e - - - d G t i v s g l e Y r k e c e c q s s F v G F i x v f L L e x E D t x t e L r L x p l r l K H R l i l f r P d x l x d F e L C x L L s a l E N l - - P l s r q T - - - L x k L l a y L r x v
HCMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - L H D L L Q Y L D A V
Chimp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T S G A G R L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V
VZV pORF53M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V S L - R V K P E H Q E T V L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L


























































































































































V G YF VTCSAI ATFVLG SAFIV SCVIF VIL VTL ADE VHEATSN E D VRQMGHAT MIVL YEDSQKHT TNSQHE TIVL NGDAKR IVL VHFNTSP KDSP TSRMIHFL LQVR VTCAFL SRQILK YERH R FVMICL TCSGAI YIHVL YTMLVF NIKR TLAVP SRNTKD SEDTN VNDPL RNGDMETL LIHED TMF LSMATE ML VAC VMALTGC VIL IVL YMFS VMYCA TVIL E GCSN IACL K S TRGNP VSPIDRL MITKS SKQHGR VPLSKAQ SCT P S TFL FL FAVRELH SQNHEADK IVL RVSIL VTSQNDGCA KIFWRY IAL QNDVTKGR TRMGDAKVL MLICAFTV GEHA4.302.2
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Ruler 1 210 220 230 240 250 260 270 280 290
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HCMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - H D L L Q Y L D A V - N V R E S F G R - - - L L H H S A R R L I C S A L Y L L F E E K E P H I V Q Y V P - A T - - - - - - F V L F Q Q - - T R H T C L Q - - - L V A R F F F - - - - - - R L T G Q D E A H S F S L K L T E R
Chimp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M - N V R D S F G K - - - L L Q H S A R R L I C S A L Y L F F E E K D A D V V E H V P - A T - - - - - - F M L Y L Q - - A R H S C L E - - - I V T R F F F - - - - - - R I T R Q D E D H V F S L K L T D R
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V - N I R D Q F S T - - - L L R I S C Q K L I C S T L Y L F F D D K T T E I V E Q V P - K V - - - - - - F I L F Y E - - S R Q S F L H - - - T I L R F W F - - - - - - R I T R Q D E S Y K V T M K L M E R
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T A R G T S S F F G - - - L V R R S C M V M T C S C L Y L F F D V S S D V I L T H V P - K T - - - - - - Y I L H Q Q - - V R R S R L D A A S A A I S G L L - - - - - - G S V V A P G D A F F S L S F A T R
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T - R P R T G L T R - - - M I C K S C I K L V C T S L Y L F F D E T D P R I T R H V P - E I - - - - - - C M L Y K E - - T Q R A Q A T - - - M L A E T Y F - - - - - - G V Q D I S S M S L V S L T L T D R
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C - N P R T G L A K - - - M I R R S C V R L I C A S L Y L F F D V Q D T R I T N R V S - Q V - - - - - - C L L Y K E - - T Q R A N A S - - - M I A E T Y F - - - - - - G K S L P A M A T L V S L S I C D R
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F - P A L S P I T K - - - I L F N T C D T L V C T L R H I F F N E H A S E I L H K V P - L M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F - P V L S P V T K - - - I L F N T C D K L V C T L R H I F F N E H A S E I L H K V P - P M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I - S V T L P V S K - - - L L A C T C Q K L I S I L R Y I F Y D D K Q Q D V L D K V P - P I - - - - - - I Q L Y Y E - - S K T A N I H - - - - M L N L F F - - - - - - K S H - - D N D D T C T L S L N T R
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A G R R T S P F E R V R C L F L R S C H W V L N T L M F M V - H V K P F D D E F V L P - H W - - - - - - Y M A R Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P T S S S F R L P G P P P
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V A R H A S P F E R V R C L L L R S C H W I L N T L M C M A - G V K P F D D E L V L P - H W - - - - - - Y M A H Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P Q S S A L Q L P G P V P
VZV pORF53M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V E C Q I G P L E K M R R F L Y E G V L W L L N T L M Y V V - D N N P F T K T R V L P - H Y - - - - - - M F V K L L N P Q P G T A P N - - - - I I K A I Y - - - - - - S C G - - - V G Q R F D L P H G T P
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L H S K C N N L D S L - - F L Y N G A R T L L S T L V - - - - K Y H D L E E G A A T P G P W N E G L S L F K L H K E - - L K R A P S E A R D L M Q S L F L T S G K M G C L A R S P K D Y C A D L N K E E D





































































V R RC MIFL FVIL QMHCAYLFR KIECNHR TGS VIAC VMLIEQHDR VWTRK VMIL TVLI ASNC IAST TCSAL VARML CHFY VMIL YLAVF YF KHGNED YNLDVE TQNSHK VTSQEAPD QLATSPDF VTHRED KHEVDI GFEVTL TQNLFDAHER YRQAVKH TLV SP LG VQLEKAPH YVIWTM N E G L S L MCYIF VQLFRKIM VAL RKFHY QNLYK AQLE N P VQIASMTL PGQARK TQGDHRN NSTA SRQFANHCP TSAPIL TSQNDHPE MA RGA SGD TIAML LAMIV TQKIAL PNKRSE IGTFAL WILFY YLF T S G K M G SKNRGC VKCTSLIA VSQHGAKT VLGDR SPIAQ SARPD VTQNMKGSE MGHASD TQFDAYNHS VTRCASLKF CALIVF RQETNDS SML TNPKS KIHFGL NMGCAPTE VPNSTED EDPR VPDAKRQ4.302.2
Ruler 2 210 220 230 240 250 260 270 280 290
Ruler 1 310 320 330 340 350
Consensust d - - r r n v r l x a p s v v d i - T V x x - d r l W f h t e - - - d G t i v s g l e Y r k e c e c q s s F v G F i x v f L L e x E D t x t e L r L x p l r l K H R l i l f r P d x l x d F e L C x L L s a l E N l - - P l s r q T - - - L x k L l a y L r x v - x v r s p f x k - - - l L r r S C r k L i C T l l Y l F F d e k d f d i l r x V P - x x - - - - - - f m L y x e - - x x x a p l e - - - - v l x l y F - - - - - - x x t - - x e x s f f s L s l e x R x t x D - - g y x v g l x l x d v l n - - - - - - - a n x f y L p - g x p k s - t - - l - - - - - - - - - - - -
HCMV pUL103F T R Q N V M I M E P Q V L D F - T V R G - D K L W L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - L H D L L Q Y L D A V - N V R E S F G R - - - L L H H S A R R L I C S A L Y L L F E E K E P H I V Q Y V P - A T - - - - - - F V L F Q Q - - T R H T C L Q - - - L V A R F F F - - - - - - R L T G Q D E A H S F S L K L T E R K T V D - - G W P V G L G L L D V L N - - - - - - - A N Y P N L P - S P P K L P P - - R W E R G E E E - - - - -
Chimp CMV pUL103V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M - N V R D S F G K - - - L L Q H S A R R L I C S A L Y L F F E E K D A D V V E H V P - A T - - - - - - F M L Y L Q - - A R H S C L E - - - I V T R F F F - - - - - - R I T R Q D E D H V F S L K L T D R K T L D - - G W A V G L A L L D V L N - - - - - - - A N F P N L P - G P P K I S P S G V L T R - - - - - - - - -
Rhesus CMV prh140M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V - N I R D Q F S T - - - L L R I S C Q K L I C S T L Y L F F D D K T T E I V E Q V P - K V - - - - - - F I L F Y E - - S R Q S F L H - - - T I L R F W F - - - - - - R I T R Q D E S Y K V T M K L M E R Q T L N - - G K L V E V A L I E V L N - - - - - - - S N F P S L P L C D P N M L - - - - - - - - - - - - - - - -
Guinea pig CMV pGP103E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T A R G T S S F F G - - - L V R R S C M V M T C S C L Y L F F D V S S D V I L T H V P - K T - - - - - - Y I L H Q Q - - V R R S R L D A A S A A I S G L L - - - - - - G S V V A P G D A F F S L S F A T R Q T R D - - G Y G V R H V M H E V V S - - - - - - - E T V A T V G P S L V K - - - - - - - - - - - - - - - - - -
Mouse CMV pM103D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T - R P R T G L T R - - - M I C K S C I K L V C T S L Y L F F D E T D P R I T R H V P - E I - - - - - - C M L Y K E - - T Q R A Q A T - - - M L A E T Y F - - - - - - G V Q D I S S M S L V S L T L T D R V T K D - - G D T V G D L A A E V L N - - - - - T V C N V F Y V P L G T N G S G V V T R W L S N D N N P K Q R M
Rat CMV pE103M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C - N P R T G L A K - - - M I R R S C V R L I C A S L Y L F F D V Q D T R I T N R V S - Q V - - - - - - C L L Y K E - - T Q R A N A S - - - M I A E T Y F - - - - - - G K S L P A M A T L V S L S I C D R R T K D - - G D L V G E L A T D V L N - - - - - T T C N V F Y I P V G L N G N - T V T Q W L S N D K T P - - - -
HHV6A pU75R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F - P A L S P I T K - - - I L F N T C D T L V C T L R H I F F N E H A S E I L H K V P - L M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q T F Y S K N G D T S S - - - - - - - - - - - - - - - - -
HHV6B pU75V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F - P V L S P V T K - - - I L F N T C D K L V C T L R H I F F N E H A S E I L H K V P - P M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q I F Y S K N E D T S S - - - - - - - - - - - - - - - - -
HHV7 pU75I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I - S V T L P V S K - - - L L A C T C Q K L I S I L R Y I F Y D D K Q Q D V L D K V P - P I - - - - - - I Q L Y Y E - - S K T A N I H - - - - M L N L F F - - - - - - K S H - - D N D D T C T L S L N T R R L Q D D S K Y L I D F L K S A I - - - - - - - - - C D A F S K E Y K M T E I E K T S L H - - - - - - - - - - -
HSV1 pUL7R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A G R R T S P F E R V R C L F L R S C H W V L N T L M F M V - H V K P F D D E F V L P - H W - - - - - - Y M A R Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P T S S S F R L P G P P P R S - D C V A Y N P A G I M G S C W A S E E V R A P L V Y WW L S - E T P K R Q T S S L F Y Q F C - - - - - - -
HSV2 pUL7A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V A R H A S P F E R V R C L L L R S C H W I L N T L M C M A - G V K P F D D E L V L P - H W - - - - - - Y M A H Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P Q S S A L Q L P G P V P R T - D C V A Y N P A G V M G S C W N S K D L R S A L V Y WW L S - G S P K R R T S S L F Y R F C - - - - - - -
VZV pORF53D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V E C Q I G P L E K M R R F L Y E G V L W L L N T L M Y V V - D N N P F T K T R V L P - H Y - - - - - - M F V K L L N P Q P G T A P N - - - - I I K A I Y - - - - - - S C G - - - V G Q R F D L P H G T P P C P D G V V Q V P P G L L N G P L R D S E Y Q K S V Y F WW L N R T M V T P K N V Q L F E T Y K N S P R V V K
EBV pBBRF2V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L H S K C N N L D S L - - F L Y N G A R T L L S T L V - - - - K Y H D L E E G A A T P G P W N E G L S L F K L H K E - - L K R A P S E A R D L M Q S L F L T S G K M G C L A R S P K D Y C A D L N K E E D A N S - - - G F T F N L F Y Q D S L L T K H F Q C Q T V L Q T L R R K C L G S D T V S K I I P - - - - - - - - -




































































































































































































































































































E P RK VQ VR MK Y4.302.2
Ruler 2 310 320 330 340 350
Ruler 1 1 10 20 30 40 50 60 70 80 90
Consensus - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f
HCMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L
Chimp CMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V
Rhesus CMV prh140 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V
Guinea pig CMV pGP103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F
Mouse CMV pM103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F
Rat CMV pE103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L
HHV6A pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F
HHV6B pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F
HHV7 pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F
HSV1 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F
HSV2 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F
VZV pORF53 M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V
EBV pBBRF2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - -
KSHV pORF42 - - - - - - - - - - - - - - - - - - - - - - - - - - M S L E R A L A R L T G V P M S T H A P K T R E S E E A C P V Y P H P V V P R L V L E V H - - - - R K N N A L V G S N T P K M - S V M G - - - - - -
Sequence Logo M Q R I R P Y W I K F E Q T G G A G M A D G M S G IM NMA SIDA LAP SET RPIA LDA LGD CAE SRG VTSL TA MIGA VTDA SPNI MGL SLK HTQM TRKHA QLSIA ELAP EAKG TSMKGD TQRL REDASK VGASLE SPFEVL TSDE MDVAT QPLICSA KPED IDAMGV YLISMF RPLDESN SRQMHATNI PQ TSVAL VTSIHLM LIPV R NMFATLG MIAV MCL KE LAV NIRH EQNKT HIVD EF SGT SKGEADR QEDLHKR YHGQKCN TNIAPV AMISR VCIFL LKIAVTM VTSGERNA SNLHTP RDQPNES TLIV TMIAPLV KERNSD MLVFI Y RNSDT LAV VTMARKSG PNGD RGEA RHCGD KDGQR VMEIL TLRW LVF RQLVH4.302.2
Ruler 2 1 10 20 30 40 50 60 70 80 90
Ruler 1 110 120 130 140 150 160 170 180 190
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L v g v L x t d - - r r n v r l x a p s v v d i - T x x - d r l f h t e - - - d G t i v s g l e Y r k e c e c q s s F v G F i x v f L L e x E D t x t e L r L x p l r l K H R l i l f r P d x l x d F e L C x L L s a l E N l - - P l s r q T - - - L x k L l a y L r x v
HCMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L I L I L F - T - L L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - L H D L L Q Y L D A V
Chimp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L I L I F - T - L Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I - L L I T T I I - T - L H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V
Guinea pig CM  pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L - T L T - T L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L - - L I I - T - I F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L - - L L I I I - T L - L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L I - L I L I I - - I L L I - T - I F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L - L I L I I - - L L I - T - I F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L I I - I L - - I L L I I - - F H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I L I L I L L L - F T T I - L F V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I L I L I L L - F T T L - T L F V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V
Z  pORF53I I I I I L I L L L I L I I - L F L L - T L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L - L L - - - - I T F - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L




















































































































































V G YF VTCSAI ATFVLG SAFIV SCVIF VIL VTL ADE VHEATSN E D VRQMGHAT MIVL YEDSQKHT TNSQHE TIVL NGDAKR IVL VHFNTSP KDSP TSRMIHFL LQVR VTCAFL SRQILK YERH R FVMICL TCSGAI YIHVL YTMLVF NIKR TLAVP SRNTKD SEDTN VNDPL RNGDMETL LIHED TMF LSMATE ML VAC VMALTGC VIL IVL YMFS VMYCA TVIL E GCSN IACL K S TRGNP VSPIDRL MITKS SKQHGR VPLSKAQ SCT P S TFL FL FAVRELH SQNHEADK IVL RVSIL VTSQNDGCA KIFWRY IAL QNDVTKGR TRMGDAKVL MLICAFTV GEHA4.302.2
Ruler 2 110 120 130 140 150 160 170 180 190
Ruler 1 210 220 230 240 250 260 270 280 290
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - v x i - v v L x t d - - r r n v r l x a p s v v d i - x x - d r l f h t e - - - d t i v s g l e r k e c e c q s s v i x v f L L e x t x t e L r L x p l r l l i l f r d x l x d e L x L L s a l l - - l s r q T - - - L x k L l a y L r x v - x v r s p f x k - - - l L r r S C r k L i C T l l Y l F F d e k d f d i l r x V P - x x - - - - - - f m L y x e - - x x x a p l e - - - - v l x l y F - - - - - - x x t - - x e x s f f s L s l e x R
HCMV pU 103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I L I L - - L L - - - L L L L L L L L L L I L L L I - - L T - - - L L L L - N V R E S F G R - - - L L H H S A R R L I C S A L Y L L F E E K E P H I V Q Y V P - A T - - - - - - F V L F Q Q - - T R H T C L Q - - - L V A R F F F - - - - - - R L T G Q D E A H S F S L K L T E R
himp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I L I - - L - - - L L L L L I L L L L L L I L - - L - - - L F L L L - N V R D S F G K - - - L L Q H S A R R L I C S A L Y L F F E E K D A D V V E H V P - A T - - - - - - F M L Y L Q - - A R H S C L E - - - I V T R F F F - - - - - - R I T R Q D E D H V F S L K L T D R
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I - L I I I - - L - - - L I L I L L L L I L L I L L - - T L T - - - L L L L L - N I R D Q F S T - - - L L R I S C Q K L I C S T L Y L F F D D K T T E I V E Q V P - K V - - - - - - F I L F Y E - - S R Q S F L H - - - T I L R F W F - - - - - - R I T R Q D E S Y K V T M K L M E R
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L - L - V L L - - - L L L L L L L L L - - T - - - L L L L T T A R G T S S F F G - - - L V R R S C M V M T C S C L Y L F F D V S S D V I L T H V P - K T - - - - - - Y I L H Q Q - - V R R S R L D A A S A A I S G L L - - - - - - G S V V A P G D A F F S L S F A T R
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L I I - - I - - - L I L L I L L L L I I L L L I L - - L T - - - L L T F L T T - R P R T G L T R - - - M I C K S C I K L V C T S L Y L F F D E T D P R I T R H V P - E I - - - - - - C M L Y K E - - T Q R A Q A T - - - M L A E T Y F - - - - - - G V Q D I S S M S L V S L T L T D R
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L I I I - L - L - - - I I L L I L L L L I L L L L L I L - - L T - - - L I L - N P R T G L A K - - - M I R R S C V R L I C A S L Y L F F D V Q D T R I T N R V S - Q V - - - - - - C L L Y K E - - T Q R A N A S - - - M I A E T Y F - - - - - - G K S L P A M A T L V S L S I C D R
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I - I L I I - - I L L I - - I L - - - I L I L I I I I L L L L L I L L L L - - L T - - - L L I L L F - P A L S P I T K - - - I L F N T C D T L V C T L R H I F F N E H A S E I L H K V P - L M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I L I I - - L L I - - I L - - - I L I L I I I I L L L L L I L L L L - - L T - - - L L I L L F - P V L S P V T K - - - I L F N T C D K L V C T L R H I F F N E H A S E I L H K V P - P M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I I - I L - - I L L I I - - L - - - I I L L I I I L L L I L I I L I L L L I L L - - I T - - - L L L I I I - S V T L P V S K - - - L L A C T C Q K L I S I L R Y I F Y D D K Q Q D V L D K V P - P I - - - - - - I Q L Y Y E - - S K T A N I H - - - - M L N L F F - - - - - - K S H - - D N D D T C T L S L N T R
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I I I - I - L L L L L L L L L L L L L L - - T T F L L G R R T S P F E R V R C L F L R S C H W V L N T L M F M V - H V K P F D D E F V L P - H W - - - - - - Y M A R Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P T S S S F R L P G P P P
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I I I - L - L L L L L L L L L L L L L L - - T L F L A R H A S P F E R V R C L L L R S C H W I L N T L M C M A - G V K P F D D E L V L P - H W - - - - - - Y M A H Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P Q S S A L Q L P G P V P
VZV pOR 53I I I I I I I I I - L L V L - L L I L L L I L L L I L L I - - L F L L E C Q I G P L E K M R R F L Y E G V L W L L N T L M Y V V - D N N P F T K T R V L P - H Y - - - - - - M F V K L L N P Q P G T A P N - - - - I I K A I Y - - - - - - S C G - - - V G Q R F D L P H G T P
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L - - - - I - - - - - - - - - - - - L I L I L L L L I I L L L L I I L - - - - L L T L L H S K C N N L D S L - - F L Y N G A R T L L S T L V - - - - K Y H D L E E G A A T P G P W N E G L S L F K L H K E - - L K R A P S E A R D L M Q S L F L T S G K M G C L A R S P K D Y C A D L N K E E D





























































V R RC MIFL FVIL QMHCAYLFR KIECNHR TGS VIAC VMLIEQHDR VWTRK VMIL TVLI ASNC IAST TCSAL VARML CHFY VMIL YLAVF YF KHGNED YNLDVE TQNSHK VTSQEAPD QLATSPDF VTHRED KHEVDI GFEVTL TQNLFDAHER YRQAVKH TLV SP LG VQLEKAPH YVIWTM N E G L S L MCYIF VQLFRKIM VAL RKFHY QNLYK AQLE N P VQIASMTL PGQARK TQGDHRN NSTA SRQFANHCP TSAPIL TSQNDHPE MA RGA SGD TIAML LAMIV TQKIAL PNKRSE IGTFAL WILFY YLF T S G K M G SKNRGC VKCTSLIA VSQHGAKT VLGDR SPIAQ SARPD VTQNMKGSE MGHASD TQFDAYNHS VTRCASLKF CALIVF RQETNDS SML TNPKS KIHFGL NMGCAPTE VPNSTED EDPR VPDAKRQ4.302.2
Ruler 2 210 220 230 240 250 260 270 280 290
Ruler 1 310 320 330 340 350
Consensust - - r r v r l x s v v i - x x - r l f t - - - t i v s l r k c c s s v i x v f x t x t r x l r l l i l f r x l x e L x L L s a l l - - l s r q - - - L x k L l a y L r x v - x v r s p f x k - - - l L r r r k L i l l l d e k d f d i l r x - x x - - - - - - f L y x e - - x x x a p l e - - - - v l x l y F - - - - - - x x t - - x e x s f f s L s l e x x t x D - - g y x v g l x l x d v l n - - - - - - - a n x f y L p - g x p k s - t - - l - - - - - - - - - - - -
HCMV pUL103I - - - - - I L I - - L - - - L L L L - - - - L L L I L L L I - - - - - - - L - - L - - - L F - - - - - - L T F L L T K T V D - - G W P V G L G L L D V L N - - - - - - - A N Y P N L P - S P P K L P P - - R W E R G E E E - - - - -
Chimp CMV pUL103I - - - - - I L I L - - L - - - L L L L - - - - L L L I L L - - - - - - - L L - - L - - - I F - - - - - - I T F L L T K T L D - - G W A V G L A L L D V L N - - - - - - - A N F P N L P - G P P K I S P S G V L T R - - - - - - - - -
hesus CMV prh140I - I I I - - - - - I I I L I L L - - L - - - L L L L L - I - - - L L I L I L L I - - - - - - - I L - - L - - - I L F - - - - - - I T T L Q T L N - - G K L V E V A L I E V L N - - - - - - - S N F P S L P L C D P N M L - - - - - - - - - - - - - - - -
Guinea pig CMV pGP103- - - - - L L L L L - - - - - L L L L - - - L L L I L - - - - - - - I L - - L I L L - - - - - - F F L F T Q T R D - - G Y G V R H V M H E V V S - - - - - - - E T V A T V G P S L V K - - - - - - - - - - - - - - - - - -
Mouse C V pM103- - I I - - I - - - I I I I L L L I L - - L - - - L L L - L - - - I I L L L I - I - - - - - - L - - - - - L F - - - - - - I L L T L T V T K D - - G D T V G D L A A E V L N - - - - - T V C N V F Y V P L G T N G S G V V T R W L S N D N N P K Q R M
Rat CMV pE103- - I I I - - - - - I I I I L L L L I L - - L - - - L I L - L - - - I L I L L I - - - - - - - L L - - - - - I F - - - - - - L T L L I R T K D - - G D L V G E L A T D V L N - - - - - T T C N V F Y I P V G L N G N - T V T Q W L S N D K T P - - - -
HHV6A pU75I I I - - I I - - I - - - I I I I I I I L L L L - - L - - - L L I L L - L I - - - I L L L I I L - L - - - - - - I L - - I - - - - L L F - - - - - - T - - F I L L Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q T F Y S K N G D T S S - - - - - - - - - - - - - - - - -
HHV6B pU75I I I - - I - - I - - - I I I I I I I L L L L - - L - - - L L I L L - L - - - I L L L I I L - - - - - - - I L - - I - - - - L L F - - - - - - T - - F I L L Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q I F Y S K N E D T S S - - - - - - - - - - - - - - - - -
HHV7 pU75I - - I I I - - - - - I I I I I I I I I L L I L L - - I - - - L L L I I I - L - - - L L L I I L I L - I - - - - - - I L - - I - - - - L L F - - - - - - - - T T L L T R L Q D D S K Y L I D F L K S A I - - - - - - - - - C D A F S K E Y K M T E I E K T S L H - - - - - - - - - - -
HSV1 pUL7- I - L L L L - - L L L L L L - L - - - - - - - L - - L - - - - L L F - - - - - - T - - T F L R S - D C V A Y N P A G I M G S C W A S E E V R A P L V Y WW L S - E T P K R Q T S S L F Y Q F C - - - - - - -
HSV2 pUL7- - L L L L - - L L L L L I L L - L L - - - - - - - L - - L - - - - L L F - - - - - - T - - L L R T - D C V A Y N P A G V M G S C W N S K D L R S A L V Y WW L S - G S P K R R T S S L F Y R F C - - - - - - -
VZV pORF53I I - - I I L I L L I - - L L L I L L L L L L - L - - - - - - - L L - - - - I I I - - - - - - - - - F L T P C P D G V V Q V P P G L L N G P L R D S E Y Q K S V Y F WW L N R T M V T P K N V Q L F E T Y K N S P R V V K
EBV pBBRF2- - - - I - - - - - - - - - - - - I I I I L L I I L - - - - L L L L L L - - L L L L - - - - L L L L - - L L L L T L L A N S - - - G F T F N L F Y Q D S L L T K H F Q C Q T V L Q T L R R K C L G S D T V S K I I P - - - - - - - - -

























































































































































































































































































E P RK VQ VR MK Y4.302.2
Ruler 2 310 320 330 340 350
Ruler 1 1 10 20 30 40 50 60 70 80 90
Consensus - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f
HCMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L
Chimp CMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V
Rhesus CMV prh140 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V
Guinea pig CMV pGP103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F
Mouse CMV pM103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F
Rat CMV pE103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L
HHV6A pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F
HHV6B pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F
HHV7 pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F
HSV1 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F
HSV2 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F
VZV pORF53 M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V
EBV pBBRF2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - -
KSHV pORF42 - - - - - - - - - - - - - - - - - - - - - - - - - - M S L E R A L A R L T G V P M S T H A P K T R E S E E A C P V Y P H P V V P R L V L E V H - - - - R K N N A L V G S N T P K M - S V M G - - - - - -
Sequence Logo M Q R I R P Y W I K F E Q T G G A G M A D G M S G IM NMA SIDA LAP SET RPIA LDA LGD CAE SRG VTSL TA MIGA VTDA SPNI MGL SLK HTQM TRKHA QLSIA ELAP EAKG TSMKGD TQRL REDASK VGASLE SPFEVL TSDE MDVAT QPLICSA KPED IDAMGV YLISMF RPLDESN SRQMHATNI PQ TSVAL VTSIHLM LIPV R NMFATLG MIAV MCL KE LAV NIRH EQNKT HIVD EF SGT SKGEADR QEDLHKR YHGQKCN TNIAPV AMISR VCIFL LKIAVTM VTSGERNA SNLHTP RDQPNES TLIV TMIAPLV KERNSD MLVFI Y RNSDT LAV VTMARKSG PNGD RGEA RHCGD KDGQR VMEIL TLRW LVF RQLVH4.302.2
Ruler 2 1 10 20 30 40 50 60 70 80 90
Ruler 1 110 120 130 140 150 160 170 180 190
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l f h t e - - - d G t i v s g l e Y r k e c e c q s s F v G F i x v f L L e x E D t x t e L r L x p l r l K H R l i l f r P d x l x d F e L C x L L s a l E N l - - P l s r q T - - - L x k L l a y L r x v
HCMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E A - L I R V L E V H T D F T R N V I E P V L D F - T V R - D K L L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - L H D L L Q Y L D A V
Chimp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E S - L I V L E V T F T K V I V P V F - T V K - L V Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A A P S P P I - L V V L E V T E T S V I V T T P I V I - T V S - L V H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L P A L E V T - E T S L V P V T V - T S A L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T - L - - L I I - T - I F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L - - L L I I I - T L - L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C
HH 6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L T F I - L T I L I I - - I L L I - T - I F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F
HH 6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L T F T - L T I L I I - - L L I - T - I F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - L L L I I - I L - - I L L I I - - H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I L I L I L L L - I - L V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - I L I L I L L - L - L V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V
Z  pORF53I I I I I L I L L L I L I I - L L L - L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - I - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L


















































































































































V G YF VTCSAI ATFVLG SAFIV SCVIF VIL VTL ADE VHEATSN E D VRQMGHAT MIVL YEDSQKHT TNSQHE TIVL NGDAKR IVL VHFNTSP KDSP TSRMIHFL LQVR VTCAFL SRQILK YERH R FVMICL TCSGAI YIHVL YTMLVF NIKR TLAVP SRNTKD SEDTN VNDPL RNGDMETL LIHED TMF LSMATE ML VAC VMALTGC VIL IVL YMFS VMYCA TVIL E GCSN IACL K S TRGNP VSPIDRL MITKS SKQHGR VPLSKAQ SCT P S TFL FL FAVRELH SQNHEADK IVL RVSIL VTSQNDGCA KIFWRY IAL QNDVTKGR TRMGDAKVL MLICAFTV GEHA4.302.2
Ruler 2 110 120 130 140 150 160 170 180 190
Ruler 1 210 220 230 240 250 260 270 280 290
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - i - m R E V t - - r r r l i - V - r l W f t - - - t i l r i f t t r l r l l i l f r l l l - - l r - - - l r - x v r s p f x k - - - l L r r S C r k L i C T l l Y l F F d e k d f d i l r x V P - x x - - - - - - f m L y x e - - x x x a p l e - - - - v l x l y F - - - - - - x x t - - x e x s f f s L s l e x R
HCMV pU 103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - M I R G V E V H T D F T R Q N V M I M E P Q V D - V R G - D K W - - - I I - - - - - - N V R E S F G R - - - L L H H S A R R L I C S A L Y L L F E E K E P H I V Q Y V P - A T - - - - - - F V L F Q Q - - T R H T C L Q - - - L V A R F F F - - - - - - R L T G Q D E A H S F S L K L T E R
himp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - M I R G V E V R T D F T K H N V M I M V P R V M D - V K D - D R W V - - - I I - - - - - - N V R D S F G K - - - L L Q H S A R R L I C S A L Y L F F E E K D A D V V E H V P - A T - - - - - - F M L Y L Q - - A R H S C L E - - - I V T R F F F - - - - - - R I T R Q D E D H V F S L K L T D R
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - M V R G V E V H T D E T S R N V I V P Q I V D I - V S N - D R W V - - - I I I I - - - - - - N I R D Q F S T - - - L L R I S C Q K L I C S T L Y L F F D D K T T E I V E Q V P - K V - - - - - - F I L F Y E - - S R Q S F L H - - - T I L R F W F - - - - - - R I T R Q D E S Y K V T M K L M E R
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - P R A M E V R T D - G E R G S V N P D V D V - V S G A G R - - - - - - - - A R G T S S F F G - - - L V R R S C M V M T C S C L Y L F F D V S S D V I L T H V P - K T - - - - - - Y I L H Q Q - - V R R S R L D A A S A A I S G L L - - - - - - G S V V A P G D A F F S L S F A T R
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - M V R G A M E V H N D - - R D Y V R M A P E I V S I - V S D - R Q I W - - - I I I I I - - - - - - R P R T G L T R - - - M I C K S C I K L V C T S L Y L F F D E T D P R I T R H V P - E I - - - - - - C M L Y K E - - T Q R A Q A T - - - M L A E T Y F - - - - - - G V Q D I S S M S L V S L T L T D R
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - M V R G A M E V H N D - - R K V R I S P E I V S I - V N - G Q M W - - - I I I I I - - - - - I - N P R T G L A K - - - M I R R S C V R L I C A S L Y L F F D V Q D T R I T N R V S - Q V - - - - - - C L L Y K E - - T Q R A N A S - - - M I A E T Y F - - - - - - G K S L P A M A T L V S L S I C D R
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S K K K E E T S D V F N I - H V R T I K V I K I - - D K C I S A R H P N I - V G D - D G I W - - - I I I I I I I - - - - - I - P A L S P I T K - - - I L F N T C D T L V C T L R H I F F N E H A S E I L H K V P - L M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S K K K E E T S D V F N T - H V R T I K V I K I - - D K C V S A R H S N I - V G D - D G I W - - - I I I I I I I - - - - - I - P V L S P V T K - - - I L F N T C D K L V C T L R H I F F N E H A S E I L H K V P - P M - - - - - - I R L Y N E - - M K N T H I E - - - - V L E L Y F - - - - - - N T K - - R S H N F I N L S L E S R
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T P A S K G F E T D I F N I - S S V R N I C E N K H - - A E H V S I K N P I D I - S V G N - D D V W - - - I I I I I I I I I I - - I - - - I I I - S V T L P V S K - - - L L A C T C Q K L I S I L R Y I F Y D D K Q Q D V L D K V P - P I - - - - - - I Q L Y Y E - - S K T A N I H - - - - M L N L F F - - - - - - K S H - - D N D D T C T L S L N T R
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I K Q A I A G D R S V E A A E A I S Q Q T R A C E V R Q V - G D R Q P R A S I A R V - D V A P G C R R - - G R R T S P F E R V R C L F L R S C H W V L N T L M F M V - H V K P F D D E F V L P - H W - - - - - - Y M A R Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P T S S S F R L P G P P P
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I K Q A I A G D R S V E V A E G I S N Q A R M A C E V R Q V - S D R Q P R A S V R V - D V P R G R R - - A R H A S P F E R V R C L L L R S C H W I L N T L M C M A - G V K P F D D E L V L P - H W - - - - - - Y M A H Y L - - L A N N P P P - - - - V L S A L F - - - - - - C A T - - P Q S S A L Q L P G P V P
VZV pORF53M Q R I R P Y I K F E Q T G G A G M A D G M S G I N I P S I G C S V T I D N T R A E E G D V S D V I E D R I Q A I P R F V C E A R E V - T G K P R A N S V V S - R V K P E H Q E V I I I I - - E C Q I G P L E K M R R F L Y E G V L W L L N T L M Y V V - D N N P F T K T R V L P - H Y - - - - - - M F V K L L N P Q P G T A P N - - - - I I K A I Y - - - - - - S C G - - - V G Q R F D L P H G T P
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S T M Q K V S R - V T P R V E V N - - - - R H N A I C V A N V P E Y N A R G - - - - - - - - - - - - I I I I I I - - - - H S K C N N L D S L - - F L Y N G A R T L L S T L V - - - - K Y H D L E E G A A T P G P W N E G L S L F K L H K E - - L K R A P S E A R D L M Q S L F L T S G K M G C L A R S P K D Y C A D L N K E E D


























































V R RC MIFL FVIL QMHCAYLFR KIECNHR TGS VIAC VMLIEQHDR VWTRK VMIL TVLI ASNC IAST TCSAL VARML CHFY VMIL YLAVF YF KHGNED YNLDVE TQNSHK VTSQEAPD QLATSPDF VTHRED KHEVDI GFEVTL TQNLFDAHER YRQAVKH TLV SP LG VQLEKAPH YVIWTM N E G L S L MCYIF VQLFRKIM VAL RKFHY QNLYK AQLE N P VQIASMTL PGQARK TQGDHRN NSTA SRQFANHCP TSAPIL TSQNDHPE MA RGA SGD TIAML LAMIV TQKIAL PNKRSE IGTFAL WILFY YLF T S G K M G SKNRGC VKCTSLIA VSQHGAKT VLGDR SPIAQ SARPD VTQNMKGSE MGHASD TQFDAYNHS VTRCASLKF CALIVF RQETNDS SML TNPKS KIHFGL NMGCAPTE VPNSTED EDPR VPDAKRQ4.302.2
Ruler 2 210 220 230 240 250 260 270 280 290
Ruler 1 310 320 330 340 350
Consensust - - r r r l i - T V - r l f t - - - G t i l Y r F G F i f E D t t r l r l K H R l i l f r P l F C l E N l - - P l r - - - l r - r f - - - l r r r i l l l f i l r - - - - - - - f - - l - - - - l l - - - - - - t - - f f l x t x D - - g y x v g l x l x d v l n - - - - - - - a n x f y L p - g x p k s - t - - l - - - - - - - - - - - -
HCMV pUL103F T R Q N V M I M E P Q V D F - T V R G - D K H T E - - - H G V S M A E Y R S E C T S A F G Y S A V F E T E D A V T Q V R S D R K H R C G I V K A D N H F A C T V I S C V E N C - - N R K C - - - H D Q Y D A V - - - - I I - - - - - - - - - - - - - - - - - - K T V D - - G W P V G L G L L D V L N - - - - - - - A N Y P N L P - S P P K L P P - - R W E R G E E E - - - - -
Chimp CMV pUL103V E V R T D F T K H N V M I M V P R V M D F - T V K D - D R V Q T V - - - Q S P M S M S E Y R A E H G T S F V G Y S T V F E T E D A I T Q K T D R V K H R C G V K P D N M H F S C T I S C V E N C - - N S R Q C - - - D S Y R M M - - - - I - - - - - - - - - - - - I - - - - - - I K T L D - - G W A V G L A L L D V L N - - - - - - - A N F P N L P - G P P K I S P S G V L T R - - - - - - - - -
hesus CMV prh140M D I - L M V R G V E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R V H T D - - - H G M C S I S E Y R G E M S K S S F V G Y S T I F E N E D V M K N V K T S M R K H R C G I V R T S N M H F T C T I S C V E N - - R K C - - - D G Y K V V - I - - - I I I - - - - - - - I - - - - - I - - - - - - I Q T L N - - G K L V E V A L I E V L N - - - - - - - S N F P S L P L C D P N M L - - - - - - - - - - - - - - - -
Guinea pig CMV pGP103E V R T D - G E R G T S V N P D V T D V - T S G A G R F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V E N E D T K E T K V K S R K H R V A V T R P T T D D D F A C Y V T E C - - P V S R V - - - A V N Y Q - - - I - - - - - - - I - - I - - - - - - Q T R D - - G Y G V R H V M H E V V S - - - - - - - E T V A T V G P S L V K - - - - - - - - - - - - - - - - - -
Mouse CMV pM103D - - R D Y V R M A P E I V S I - T V S D - R Q I F H T E - - - S G E I P N A Q Y R A D S D C R S S F G F C F F I D A E D A S E R S S I R T K H R I A V F R P K T N T D F T C M F A I E S - - P S R Q - - - E H V G - - - - I I I - I - - - - - - - - - - - - - - - - - I V T K D - - G D T V G D L A A E V L N - - - - - T V C N V F Y V P L G T N G S G V V T R W L S N D N N P K Q R M
Rat CMV pE103M V R G A M E V H N D - - R K V R I S P E I V S I - T V N - G Q M H T E - - - S G K I I P H Q Y R T E V E C K T S F V G F C F F I E E E D G S E R T S I R A R H R A V F R P K T N T D F S C Y A I E S - - P S K Q - - - E N I V C Y N D C - - - - I I I - - - - - - - - - - - - I - - - - - - I R T K D - - G D L V G E L A T D V L N - - - - - T T C N V F Y I P V G L N G N - T V T Q W L S N D K T P - - - -
HHV6A pU75R T I K V I K I - - D K C I S A R H P N I - T V G D - D G I F H E - - - D G T M I N G E Y K T I C E K E G F Q G F I G I I I D S E D T Q E R N P F Q F K R R I H M K V D T P E E F M C G V F A E N - - P K Q S - - - H K I A K V - I - - - I I I - - - - - - - I - - I - - - - - - - - - - - - I Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q T F Y S K N G D T S S - - - - - - - - - - - - - - - - -
HHV6B pU75V R T I K V I K I - - D K C V S A R H S N I - T V G D - D G I F H E - - - D G T M I N G E Y K T I C E K E G F Q G F I G I I I D S E D T Q E R N P F Q F K R R I H M K V D T P E E F M C G V F A E N - - P K Q S - - - H K I A R V - - - - I I I - - - - - - - I - - I - - - - - - - - - - - - I Q L Q D S S L Q V I Q L A T - - - - - - - - - - Q F A Q I F Y S K N E D T S S - - - - - - - - - - - - - - - - -
HHV7 pU75I C E N K H - - A E H V S I K N P I D I - S V G N - D D V F H E - - - D G T I V N G K S Y K S I C E K T G F G F I G I I D S E D T E E I R S K T Q C K R R I I Y I K E D T E F C G I V Y A E N - - P I K G Q - - - K R D I I K K I - - - - I I I - I - - - - - - I - - I - - - - - - - - - - - - R L Q D D S K Y L I D F L K S A I - - - - - - - - - C D A F S K E Y K M T E I E K T S L H - - - - - - - - - - -
HSV1 pUL7R Q V - G D R Q P R F T A T S I A R V - D V A P G C R R F V D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V T A N E D H V H S A V P P V H R F S F N P R D D F E A C M Y E N C - - P R S H A P S A K V A W G V A - - - - - - - - - - - - - - - - - - - - - - R S - D C V A Y N P A G I M G S C W A S E E V R A P L V Y WW L S - E T P K R Q T S S L F Y Q F C - - - - - - -
HSV2 pUL7A L L R M A C E V R Q V - S D R Q P R F T A T S V R V - D V T P R G R R F V D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V T A N E D H V H S A V P P V H R S F R P T D R D F E V C M Y E N C - - P R S H A P S V K V S A W G V V I - - - - - - - - - - - - - - - - - - - - - - R T - D C V A Y N P A G V M G S C W N S K D L R S A L V Y WW L S - G S P K R R T S S L F Y R F C - - - - - - -
VZV pORF53D L R I Q A I P R F V C E A R E V - T G K P R F A N S V S - R V K P E H Q E T V V V N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V T A V E D R V Y T V G V P P R I Y R M T F R P D N V D F T C V I M Y E G I - - G P S G A S P S V Q S V Y R R V I - - - - - - - - - - - - I I I - - - - - - - - - P C P D G V V Q V P P G L L N G P L R D S E Y Q K S V Y F WW L N R T M V T P K N V Q L F E T Y K N S P R V V K
EBV pBBRF2V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - - - - - - - - D N I R D R A H V K A R M I S S Q F C G Y V V S D S E D Q V D H N I F P H V F S E R M I Y K P N N V N M E M C A S M I E N A K S P S I G C - - - - R E V G R - - - - - - - - A N S - - - G F T F N L F Y Q D S L L T K H F Q C Q T V L Q T L R R K C L G S D T V S K I I P - - - - - - - - -

























































































































































































































































































E P RK VQ VR MK Y4.302.2
Ruler 2 310 320 330 340 350
Ruler 1 1 10 20 30 40 50 60 70 80 90
Consensus - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f
HCMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L
Chimp CMV pUL103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V
Rhesus CMV prh140 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V
Guinea pig CMV pGP103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T V S G A G R L L F
Mouse CMV pM103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F
Rat CMV pE103 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L
HHV6A pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L V N I - T V G D - D G I W F
HHV6B pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L V N I - T V G D - D G I W F
HHV7 pU75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F
HSV1 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F
HSV2 pUL7 - - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F
VZV pORF53 M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V V S L - R V K P E H Q E T V
EBV pBBRF2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - -
KSHV pORF42 - - - - - - - - - - - - - - - - - - - - - - - - - - M S L E R A L A R L T G V P M S T H A P K T R E S E E A C P V Y P H P V V P R L V L E V H - - - - R K N N A L V G S N T P K M - S V M G - - - - - -
Sequence Logo M Q R I R P Y W I K F E Q T G G A G M A D G M S G IM NMA SIDA LAP SET RPIA LDA LGD CAE SRG VTSL TA MIGA VTDA SPNI MGL SLK HTQM TRKHA QLSIA ELAP EAKG TSMKGD TQRL REDASK VGASLE SPFEVL TSDE MDVAT QPLICSA KPED IDAMGV YLISMF RPLDESN SRQMHATNI PQ TSVAL VTSIHLM LIPV R NMFATLG MIAV MCL KE LAV NIRH EQNKT HIVD EF SGT SKGEADR QEDLHKR YHGQKCN TNIAPV AMISR VCIFL LKIAVTM VTSGERNA SNLHTP RDQPNES TLIV TMIAPLV KERNSD MLVFI Y RNSDT LAV VTMARKSG PNGD RGEA RHCGD KDGQR VMEIL TLRW LVF RQLVH4.302.2
Ruler 2 1 10 20 30 40 50 60 70 80 90
Ruler 1 110 120 130 140 150 160 170 180 190
Consensus- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - e - - - v x n i - L m v R g v L E V x t d - - r r n v r l x a p s v v d i - T V x x - d r l W f h t e - - - d G t i v s g l e Y r k e c e c q s s F v G F i x v f L L e x E D t x t e L r L x p l r l K H R l i l f r P d x l x d F e L C x L L s a l E N l - - P l s r q T - - - L x k L l a y L r x v
HCMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E A - L M I R G V L E V H T D F T R Q N V M I M E P Q V L D F - T V R G - D K L W L H T E - - - H G L L V S M A E Y R S E L L C T S A F L G Y S A V F L L E T E D A V T Q V R L S D L R L K H R C G I V K A D N L L H F A L C T V I S C V E N C - - N L T R K C - - - L H D L L Q Y L D A V
Chimp CMV pUL103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M E S - L M I R G V L E V R T D F T K H N V M I M V P R V M D F - T V K D - D R L W V Q T V - - - Q S P M L S M S E Y R A E L L H G T S F V G Y S T V F L L E T E D A I T Q L K L T D L R V K H R C G L V K P D N L M H F S L C T I L S C V E N C - - N L S R Q C - - - L F D L L S Y L R M M
Rhesus CMV prh140- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M Q A A P S D P P G M D I - L M V R G V L E V H T D E T S R N V I V T T P Q I V D I - T V S N - D R L W V H T D - - - H G M L C S I S E Y R G E M S L K S S F V G Y S T I F L L E N E D V M K N V K L T S M R L K H R C G I V R T S N L M H F T L C T I L S C V E N L - - T L T R K C - - - L L D L L G Y L K V V
Guinea pig CMV pGP103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M - L L P R A M L E V R T D - G E R G T S L V N P D V T D V - T S G A G R L L F R T E - - - S G R E M S A H E Y R A E R A C N H A Y Y G F A F V F V L E N E D T L K E T K L V K S R L K H R V A V T R P T T D D D F A L C L L L Y V T E C L - - P V S R V T - - - L L A V L N Y L Q T T
Mouse CMV pM103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S S T - L M V R G A M E V H N D - - R D Y V R L M A P E I V S I - T V S D - R Q I W F H T E - - - S G E L I P N A Q Y R A D S D C R S S F L G F C L F F I L D A E D A L S E L R L S S I R T K H R I A V F R P K T N T D F T L C M L L F A I E S L - - P L S R Q T - - - L E H L V T F L T G T
Rat CMV pE103- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S N N - L M V R G A M E V H N D - - R L K V R L I S P E I V S I - T L V N - G Q M W L H T E - - - S G K I I P H L Q Y R T E V E C K T S F V G F C L F F I L E E E D G L S E L R L T S I R A R H R L A V F R P K T N T D F S L C L L L Y A I E S L - - P L S K Q T - - - L E N I V C Y L N D C
HHV6A pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N I - L H V R T I L K V I K I - - D K C I S L A R H P L N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A K L V L F
HHV6B pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M K S L K K L K E L E T S D V F N T - L H V R T I L K V I K I - - D K C V S L A R H S L N I - T V G D - D G I W F H L E - - - D G T M I N G L E Y K T I C E K E L G F Q G F I G I I I L D S E D T L Q E L R L N P F Q F K R R L I H M K V D T P E E F M L C G L V F A L E N L - - P L K Q S T - - - L H K L I A R L V L F
HHV7 pU75- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M T L P A S L K G F E T L D I F N I - S S V R N I C E L N K H - - A E H V S I K N L P L I D I - S V G N - D D V W F H L E - - - D G T I V N G K S Y K S I C E K T L G F L G F I G I I L L D S E D T L E E I R L S K T Q C K R R I I Y L I L K E D T E F L L C G I V Y A L E N L - - P I K G Q T - - - L L K L R D I I K K I
HSV1 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A A A T A D D E G S A A T I L K Q A I A G D R S L V E A A E A I S Q Q T L L R L A C E V R Q V - G D R Q P R F T A T S I A R V - D V A P G C R L R F V L D G S P E D A Y V T S E D Y F K R C C G Q S S Y R G F A V A V L T A N E D H V H S L A V P P L V L L H R F S L F N P R D L L D F E L A C L L M Y L E N C - - P R S H A T P S T F A K V L A W L G V A
HSV2 pUL7- - - - - - - - - - - - - - - - - - - - - - - - - M A D P T P A D E G T A A A I L K Q A I A G D R S L V E V A E G I S N Q A L L R M A C E V R Q V - S D R Q P R F T A T S V L R V - D V T P R G R L R F V L D G S S D D A Y V A S E D Y F K R C G D Q P T Y R G F A V V V L T A N E D H V H S L A V P P L V L L H R L S L F R P T D L R D F E L V C L L M Y L E N C - - P R S H A T P S L F V K V S A W L G V V
VZV pORF53M Q R I R P Y W I K F E Q T G G A G M A D G M S G I N I P S I L G C S V T I D N L L T R A E E G L D V S D V I E D L R I Q A I P R F V C E A R E V - T G L K P R F L A N S V S L - R V K P E H Q E T V L V V L N G D S S E V S C D R Y Y M E C V T Q P A F R G F I F S V L T A V E D R V Y T V G V P P R L L I Y R M T L F R P D N V L D F T L C V I L M Y L E G I - - G P S G A S P S L F V Q L S V Y L R R V
EBV pBBRF2- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M A S G K H H Q P G G T R S L T M Q K V S L R - V T P R L V L E V N - - - - R H N A I C V A T N V P E F Y N A R G - - - - - - - - - - - - D L N I R D L R A H V K A R M I S S Q F C G Y V L V S L L D S E D Q V D H L N I F P H V F S E R M I L Y K P N N V N L M E M C A L L S M I E N A K S P S I G L C - - - - R E V L G R L T L L


























































































































































V G YF VTCSAI ATFVLG SAFIV SCVIF VIL VTL ADE VHEATSN E D VRQMGHAT MIVL YEDSQKHT TNSQHE TIVL NGDAKR IVL VHFNTSP KDSP TSRMIHFL LQVR VTCAFL SRQILK YERH R FVMICL TCSGAI YIHVL YTMLVF NIKR TLAVP SRNTKD SEDTN VNDPL RNGDMETL LIHED TMF LSMATE ML VAC VMALTGC VIL IVL YMFS VMYCA TVIL E GCSN IACL K S TRGNP VSPIDRL MITKS SKQHGR VPLSKAQ SCT P S TFL FL FAVRELH SQNHEADK IVL RVSIL VTSQNDGCA KIFWRY IAL QNDVTKGR TRMGDAKVL MLICAFTV GEHA4.302.2
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FIG 2-7 The N terminus (residues 1-125) of pUL103 is more conserved than the C terminus 
(residues 126-249).  Similarity plot of pUL103 and 59 of its homologs from across the three 
subfamilies of the Herpesviridae with a sliding window of 5, generously provided by Dr. 
Richard Roller.  y-axis scale: 0 (no similarity across residues) to 8 (identical residues).  The 
green and red lines represent the average conservation scores of the N and C termini, 
respectively.  The conserved herpesvirus domain consists of residues 65-91.  Positions that have 




































FIG 2-8 I-TASSER is a useful tool that provided predicted structures for the pUL103 
homologs whose structures had not been crystallized.  (A) Predicted structures of HCMV 
pUL103 in green, (B) HSV-1 pUL7 in blue, and (C) EBV BBRF2 in pink produced by I-
TASSER.  The conserved herpesvirus domain is indicated in each structure by the red colored 
residues.  The light purple and blue colored residues within the predicted pUL103 structure 
represent the DEAD/DEAH box and late domains, respectively.  The pUL103 and pUL7 



















FIG 2-9 There are differences in the predicted structures of the pUL103 homologs.  (A) 
Pymol super alignment of the predicted structures of pUL103 and pUL7 with an alignment score 
of 321.  (B) Pymol super alignment of the predicted structures of pUL103 and BBRF2 with an 






















                                                             
FIG 2-10 Heatmap showing alternating regions of movement within the predicted pUL103 
structure.  In the main panel, root mean square deviation (RMSD) for the individual residues of 
the predicted pUL103 structure for a total of 10 nanoseconds.  In the side panel, the average 

















FIG 2-11 Nucleotidyl transferases make up the list of the top ten structural analogs of the 
predicted pUL103 structure.  These proteins were identified by I-TASSER and come from a 
very diverse range of eukaryotes. 
  
Protein TM-Score Species Accession #
Terminal uridylyltransferase 7 catalytic module (TUT7) 0.869 H. sapiens 5W0B_A
Mitochondrial poly(A) RNA polymerase  (mtPAP) 0.846 G. gallus 5A2V_A
Terminal uridylyltransferase 1 (TUT1) 0.825 H. sapiens 5WU1_A
Cid1 poly(U) polymerase (CID1) 0.800 S. pombe 4EP7_A
RNA editing TUTase 1 (RET1) 0.785 T. brucei 3HIY_A
RNA editing terminal uridylyl transferase 2 (RET2) 0.771 T. brucei 2B51_A
Terminal uridylyl transferase 4 (TUT4) 0.765 T. brucei 2Q0E_A
RNA Editing terminal uridylyl transferase  1 (RET1) 0.759 T. brucei 5HZD_A
Poly(A) polymerase complex  GLD-2-GLD-3 (PAPGLD2GLD3) 0.759 C. elegans 4ZRL_A




FIG 2-12 The predicted structure of pUL103 aligned well with the structure of the catalytic 
domain of the human terminal uridylyl transferase 7 (TUT7) protein.  (A) Predicted 
structure of HCMV pUL103.  (B) Structure of the catalytic domain of the human terminal 
uridylyl transferase 7 (TUT7) protein.  (C) Pymol super alignment of the predicted structure of 
pUL103 and the structure of human TUT7 with an alignment score of 426.  Alpha helices are 
colored deep purple, beta strands fuschia, loops green, and the conserved herpesvirus domain 
red.  The predicted pUL103 structure pictured here was created in 2018, but does not vary 

































FIG 2-13 pUL103 homologs share protein chemistry with several nucleotidyl transferases.  
DNASTAR MUSCLE alignment (using default settings) of the HCMV pUL103, HSV-1 pUL7, 
and EBV BBRF2 protein sequences with 10 nucleotidyl transferases, structural analogs of 
predicted pUL103 structure, determined by I-TASSER.  Regions that did not align with any of 
the herpesviruses were removed.  The annotated helices and beta strands in the alignment are 























    













    













    








































    









    









    





    




































































































































































































































































FIG 2-14 The predicted structure of pUL103 aligned well with the structure of the non-
catalytic domain of the human terminal uridylyl transferase 4 (TUT4) protein.  (A) 
Predicted structure of HCMV pUL103.  (B) Structure of the non-catalytic domain of the human 
terminal uridylyl transferase 4 (TUT4) protein.  (C) Pymol super alignment of the predicted 
structure of pUL103 and the structure of human TUT4 with an alignment score of 388.  The light 
purple and blue colored residues within the predicted pUL103 structure represent the 
DEAD/DEAH box and late domains, respectively.  The pUL103 predicted structure pictured 






















FIG 2-15 There are differences between the predicted pUL7 structure and the actual 
crystallized protein.  (A) Predicted structure of HSV-1 pUL7.  Conserved herpesvirus domain 
colored red.  (B) Actual structure of the pUL7 protein from HSV-1.  (C) Pymol super alignment 






















CHAPTER 3: IDENTIFICATION OF THE TEMPORAL WINDOW WHEN PUL103 IS 
REQUIRED FOR MAXIMAL CYTOPLASMIC VIRION ASSEMBLY COMPARTMENT 
ABUNDANCE 
Introduction 
HCMV is a global, opportunistic pathogen that causes organ-specific damage and 
inflammation in immunocompromised (HIV/AIDS patients, transplant recipients) and 
immunodeficient (fetuses, infants) populations.  Immunocompromised individuals experience 
organ-specific inflammatory conditions such as hepatitis, pancreatitis, pneumonitis, enteritis, 
retinitis meningitis and encephalitis.  Immunodeficient individuals experience liver, lung, and 
spleen pathology, petechiae, hearing loss, and neurodevelopmental disabilities (64, 67).  HCMV 
is the most common viral congenital infection, as well as the leading cause of birth defects and 
childhood disabilities in the United States (49, 67).  More children suffer from CMV-related 
diseases than from more well-known congenital conditions such as Down syndrome, fetal alcohol 
syndrome, or spina bifida (16).  The virus is also the most common, nonhereditary cause of hearing 
loss in children (43).  Given its societal importance, the development of effective algorithms for 
early-life detection of congenital HCMV (77), and the limited array of therapeutic options for 
HCMV, more research is needed to uncover the mechanisms of HCMV replication and 
pathogenesis, to enable development of novel therapeutics. 
HCMV has the largest genome of all human viruses (~ 236 kb) (33, 73, 74).  This large 
and complex genome encodes at least 167 proteins, four large, noncoding RNAs, two oriLyt 
RNAs, and at least 23 microRNAs (64).  Technology such as ribosome profiling has shown that 
the HCMV genome may have the capacity to encode at least 751 open reading frames; this includes 
short functional proteins of less than 100 amino acids (37, 96).  HCMV virions are complex 
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particles consisting of four components: (a) an outer envelope made up of a lipid bilayer and 
embedded proteins, (b) a layer of proteins and RNA called the tegument, (c) a proteinaceous 
capsid, and (d) the viral genome that resides within the capsid (74).  The HCMV virion consists of 
thousands of individual components that need to be intricately assembled to form an infectious 
particle.  To enable this, HCMV reorganizes infected cells into virus-producing factories, in which 
the cellular endosecretory machinery, consisting mostly of Golgi membranes and early or 
recycling endosomes, is remodeled into the cytoplasmic virion assembly compartment (cVAC). 
The cVAC is a hallmark of HCMV infection (84, 85).  It is a juxtanuclear complex 
consisting of the Golgi reorganized into a ring-like structure with early and recycling endosomes 
primarily in the center of the ring (28).  Other components of the secretory machinery, such as late 
endosomes and the endoplasmic reticulum (ER), are located at the periphery of the cVAC (12, 27, 
113).  Microtubules radiating from the microtubule organizing center (mTOC) located at the center 
of the cVAC, attach to the nuclear membrane via SUN and KASH domain proteins and induce 
nuclear bending that results in the characteristic reniform shape of the nucleus (5, 11).  Within the 
cVAC, nascent capsids acquire their outer tegument, undergo secondary envelopment, and are then 
trafficked to the cellular membrane for release into the extracellular milieu (28, 89).  Each infected 
cell has one cVAC, even cells with multiple nuclei.  The cVAC is induced in various types of 
HCMV-infected cells in vitro (17, 23, 28, 53, 87, 89); unpublished data suggests this structure also 
exists in HCMV-infected tissues in vivo (C. Lim and P. Pellett). 
cVAC biogenesis is a complex, multifactorial process.  In prior studies we showed that 
cVAC formation leads to shifts in organelle identities, as defined by infection-induced changes in 
their composition, structure, localization, and function (27).  cVAC biogenesis relies upon several 
viral components, including HCMV miRNAs and the late proteins pUL48, pUL94, pUL103, and 
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gpUL132 (26, 45, 106).  cVACs still form but are less abundant when pUL103 is knocked down 
using either siRNAs or a system in which pUL103 stability is regulated (8, 26). 
The stability regulation system employed a virus, UL103-FKBP-V5, in which the FKBP 
destabilization domain is fused to the C terminus of pUL103, to produce the fusion protein 
pUL103-FKBP-V5.  In the absence of the stabilizing ligand Shield-1, the fusion protein is rapidly 
shuttled to the proteasome for degradation.  When Shield-1 is present, the fusion protein is 
stabilized and able to carry out its functions.  After knockdown of pUL103, cVACs still form, 
albeit in reduced numbers; this is likely due to redundancy among viral contributors to cVAC 
biogenesis and incomplete knockdown of pUL103 activity.   
pUL103 is transcribed and translated from the late gene UL103, located within the unique 
long region of the HCMV genome (64).  pUL103 is a small (249 amino acids, ~27.39 kDa), 
conserved tegument protein, with homologs in all members of the Herpesviridae (72, 74).  As a 
tegument protein, pUL103 is present in virions and dense bodies.  Within these particles, pUL103 
makes up a very small fraction of the total amount of protein, around 0.1% (102).  Thus, at the 
initiation of infection very little pUL103 is present.  As a late gene product, pUL103 expression is 
low early in infection and ramps up late in infection.  At 120 hours post-infection (hpi), the 
majority of pUL103 is in the cytoplasm within the cVAC, with a small amount in the nucleus (72). 
Several studies have examined the roles of pUL103 during HCMV infection (Table 1).  In 
pUL103 knockout experiments, viral titers were 10 - 10,000-fold less (1, 35, 110).  In knockdown 
experiments, pUL103 was important for cell-to-cell spread and virion maturation, in addition to 
cVAC biogenesis (26).  pUL103 may also have other roles throughout HCMV infection due to its 
presence in nuclei and interactions with cellular proteins involved in innate immune system 
signaling and intracellular trafficking (72).   
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pUL103 does not act alone during HCMV infection.  Its most noted interaction partner is 
HCMV pUL71.  These proteins form a complex that is thought to be important for proper cVAC 
formation, efficient secondary envelopment, and virion egress (14, 38, 72).  pUL103 homologs in 
other herpesviruses have been studied as well.  HSV-1 pUL7 is important for virion production, 
cell-to-cell spread, secondary envelopment, stabilization of pUL51, and maintenance of focal 
adhesions (3, 14, 98).  EBV BBRF2 is important for cell-to-cell spread and stabilization of BSRF1 
(60).  KSHV ORF42 is important for virion production (13).  These pUL103 homologs also 
interact with their respective pUL71 homologs (HSV-1 pUL51, EBV BSRF1, KSHV ORF55), an 
interaction that appears to be conserved across the Herpesviridae (3, 14, 60, 80, 108).   
Given the many roles pUL103 has throughout HCMV infection, it has potential as an 
antiviral target.  While we know pUL103 is involved in many activities during HCMV infection, 
its mechanisms of action are unknown.  In-depth mechanistic studies of pUL103 are required to 
understand how this protein contributes to HCMV infection and to design inhibitors against it. 
HCMV has a long reproductive cycle, during which it takes 48-72 hours for appreciable 
numbers of new virions to be produced (64), after which, virion production continues for several 
days.  Because of the long and complex replication cycle of the virus, some mechanistic studies of 
pUL103 would be enhanced by knowing when it is required during HCMV infection.  Thus, in 
this work we sought to identify the temporal window when pUL103 is required for maximal cVAC 
abundance and stability.  We found that for maximal cVAC abundance, pUL103-FKBP-V5 needs 
to be stabilized no later than 72 to 84 hpi during a 120-hour infection.  We also found that 
destabilization after 84 hpi results in production of fewer cVACs; it thus takes between 33 and 36 
hours for the effects of pUL103-FKBP-V5 destabilization to become apparent.  Our results suggest 
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that the period between 72 and 84 hpi would be highly informative for detailed study of the 
mechanistic roles of pUL103 in cVAC biogenesis. 
Materials and Methods 
Cells and viruses.  Human foreskin fibroblasts (HFFs) passage < 15 were used for 
experiments.  HFFs were used for growing virus stocks and plaque assays.  HFFs were grown in 
Dulbecco’s modified Eagle medium (DMEM) containing high glucose, L-glutamine, and sodium 
pyruvate (HyClone, SH30243.FS, Pittsburgh, PA) supplemented with 10% fetal bovine serum 
(FBS, S11150, Atlanta Biologicals, Flowery Branch, GA), 1x GlutaMAX (Gibco, 35050061, 
Waltham, MA), and 1x nonessential amino acids (NEAA, HyClone, SH3023801, Pittsburgh, PA) 
known as complete DMEM (cDMEM).  The bacterial artificial chromosome (BAC) containing 
HCMV pAD/Cre AD169 with 3’ FKBP and V5 tags on UL103 (UL103-FKBP-V5) was 
constructed and used as previously described (26) (Table 1).  A BAC containing HCMV pAD/Cre 
AD169 with 3’ V5 and His tags on UL103 (UL103-V5-His) was also used in this study (72) (Table 
1). Virus stocks were obtained by infecting 100% confluent HFFs at a multiplicity of infection 
(MOI) of 0.001.  While growing the UL103-FKBP-V5 virus, Shield-1, at 1 µmol, was replenished 
every 72 hours.  When 100% cytopathic effect (CPE) was reached, cells and supernatant were 
removed from flasks and centrifuged at 1280xg for 15 minutes at 4°C.  All but ~1 ml of supernatant 
was removed.  A milliliter of 10% 3x autoclaved milk was added to the supernatant and the pellet 
was resuspended. The cell suspension was sonicated three-times in a Branson analog 450 sonifier 
cup horn filled with ice water at an output control of 10 and 30% duty cycle for 10 seconds, 
followed by 10 seconds of rest.  Sonicated material was centrifuged at 1280xg for 10 minutes at 
4°C, and the supernatant was stored at -80°C.  Virus titers were determined by performing plaque 
assays using confluent layers of HFFs.   
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Immunoblots.  Unsynchronized HFFs were seeded at 80% confluence (4.22 x 105 cells) 
into 6-well plates.  The following day, cells were left uninfected or infected with the virus UL103-
FKBP-V5, in the absence or presence of Shield-1, at a multiplicity of infection (MOI) of 0.1 for 
120 hpi.  Shield-1 was replenished at 72 hpi.  Every 24 hours, infections were stopped and 
harvested for protein using RIPA (radio-immunoprecipitation assay) buffer (10 mM HEPES [pH 
7.4], 1x protease inhibitors (Roche, Indianapolis, IN or Thermo Fisher Scientific, A32961, 
Waltham, MA), 1% sodium deoxycholate, 150 mM NaCl, 1% Nonidet P-40, and 0.1% SDS).  The 
RIPA-soluble protein fractions were collected and stored at -80°C.  Protein was quantified by the 
Pierce bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, 23227, Waltham, MA).  For cell 
lysates, 30 µg of protein was solubilized in 4x SDS-Laemmli buffer followed by SDS-PAGE.  
Separated proteins were transferred to nitrocellulose membranes (Amersham Protran 0.1 µm pore 
size, 0600010, GE Healthcare Life Sciences, Chicago, IL), probed with primary antibodies 
(GAPDH, Thermo Fisher Scientific, MA5-15738; IE2, Millipore, MAB810; UL44, Virusys, 
G0729146; V5, Santa Cruz Biotechnology, sc-271944), and then reacted with horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (Bio-Rad, 1706516, 
Hercules, CA).  Reactions were detected with the SuperSignal West pico chemiluminescent 
substrate (Invitrogen, 34580, Waltham, MA) on autoradiography film (MidSci, BX810, St. Louis, 
MO). 
Immunofluorescence assay (IFA).  8-well glass chamber slides (Nunc LabTek II-154534, 
Thermo Fisher Scientific, Waltham, MA) were incubated for 1 hour at 37°C with 300 µl of 0.2% 
gelatin in 1x PBS.  Unsynchronized human foreskin fibroblasts (HFFs) were seeded at 80% 
confluence, equaling 3.52 x 104 cells, into the gelatin-coated slides.  For checking for overlaps in 
the localization of the Golgi marker GM130 and the viral marker IE2, the following day the cells 
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were infected with UL103-V5-His at an MOI of 0.1 for 120 hpi.  For the Shield-1 time course 
experiments, the following day the cells were infected with UL103-FKBP-V5 (in the absence of 
Shield-1, with Shield-1 present the entire infection, and with Shield-1 added at various times post 
infection) at an MOI of 0.1 for 120 or 144 hours.  At the end of the infections, the cells were fixed 
with 300 µl of 4% paraformaldehyde in 1x PBS for 15 min., incubated with 300 µl of 50 mM 
ammonium chloride to quench autofluorescence for 15 min., permeabilized with 300 µl of 
blocking buffer (5%, glycine, 10% normal goat serum, 0.1% sodium azide in 1x PBS) containing 
0.2% Triton X for 15 min., incubated with blocking buffer for 1 hour, removed media chamber 
and incubated with 75 µl of primary antibodies (GM130, BD Biosciences, 610823; IE2, Millipore, 
MAB810; V5, abcam, ab9116) diluted in blocking buffer for 1 hour, washed 2x for 7 min. in 1x 
PBS, incubated with 75 µl of  fluorescence-tagged secondary antibodies (Alexa Fluor 488-
conjugated goat anti-rabbit IgG (green), A-11034 and Alexa Fluor 568-conjugated goat anti-mouse 
IgG (red), A-11031, Invitrogen, Waltham, MA) diluted in blocking buffer for 1 hour, washed 2x 
for 7 min. in 1x PBS, mounted with VectaShield mounting medium with DAPI (Vector 
Laboratories, H1200, Burlingame, CA) and sealed with a coverslip (Fisherbrand, 12-548-5E, L-
50 x W-22 mm, thickness 0.13 to 0.17mm, Waltham, MA) using clear top coat nail polish (wet n 
wild, Los Angeles, CA)(Loreal, Paris, France).  Imaging was done on Nikon E800 and E600 
microscopes. 
Image analysis.  The FIJI image processing program was used to visualize the 
immunofluorescent images and MIPAR image analysis software used to threshold and measure 
nuclei (90, 95).  Infected cells late in infection and cVACs were counted and the percentage of 
cells with mature cVACs was calculated.  During infection, HCMV causes cells to swell or become 
enlarged (cytomegaly) (69).  Related to this, late in infection, infected cells have larger nuclear 
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cross-sections than uninfected cells.  pUL103 is a product of the UL103 late gene and is indicative 
of cells late in infection as well.  In our experiments, cells late in infection were defined as having 
(a) a nuclear area greater than 200 µm2 (based on comparisons of histograms of nuclear areas 
between infected and uninfected cells) and (b) visible IE2 and pUL103-FKBP-V5 staining.  
cVACs were defined by the presence of a juxtanuclear Golgi ring.  At least 30 late infection cells 
per condition were counted and statistical analysis performed.  
Statistical analysis.  Chi-square analyses were performed using GraphPad Prism version 
8.4.3 for MacOS, GraphPad Software, San Diego, California USA, www.graphpad.com. 
Results 
Experimental overview.  To identify the period when pUL103 is needed for maximal 
cVAC abundance, as detailed in Materials and Methods, we determined the relative abundance of 
cVACs produced as a function of pUL103 stabilization with Shield-1, using the UL103-FKBP-V5 
virus, which allows regulation of pUL103-FKBP-V5 stability, and thereby cVAC abundance (26).   
Time course of HCMV protein expression in cells infected with the UL103-FKBP-V5 
virus in the presence and absence of Shield-1.  To extend from our prior studies, we used 
immunoblots to examine the time course of expression of HCMV proteins IE1 and IE2 (immediate 
early), UL44 (early), and pUL103-FKBP-V5 (late) in infections with the UL103-FKBP-V5 virus, 
in the presence and absence of Shield-1, every 24 hours during a 120-hour infection (Fig. 3-1).  As 
expected, in the presence of Shield-1, pUL103-FKBP-V5 (a late protein) abundance increased over 
the course of the infection; we attribute the residual pUL103-FKBP-V5 in the absence of Shield-
1 to its incomplete the protein’s incomplete degradation by the proteasome.  This could be due to 
the proteasome being either overloaded or otherwise affected by HCMV or the FKBP fusion 
protein is not delivered to the proteasome.  The presence or absence of Shield-1 did not affect IE1 
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levels until 120 hpi, when they decreased in the absence of Shield-1.  IE2 and UL44 levels were 
reduced throughout the infection in the absence of Shield-1.  This is likely due to less cell-to-cell 
spread during low MOI infections when pUL103-FKBP-V5 is not stabilized (26).  This could also 
be due to pUL103-FKBP-V5 having potential effects on protein expression due to its conserved 
herpesvirus domain (Fig. 1-8); this domain is also present in the topoisomerase III of yeast and 
may allow binding to nucleic acids.  This further illustrates the importance of pUL103 in HCMV 
biology.  Collectively, this data demonstrates that in the presence of Shield-1, the UL103-FKBP-
V5 virus gene expression program proceeds as expected. 
The immunofluorescence signals of cytoplasmic Golgi marker GM130 and nuclear 
viral marker IE2 do not overlap in HCMV-infected cells.  The Golgi ring is a defining 
characteristic of the cVAC (5, 26, 28, 87, 93).  As part of developing a more robust method for 
quantification of cVACs, we validated simultaneous use of antibodies against the Golgi marker 
GM130, and a nuclear marker of infection IE2.  To rule out the possibility that IE2 and GM130 
staining overlap, we stained separate wells with one or the other mouse primary antibody, and then 
used the same fluorescently- tagged secondary antibody, to look for colocalization with DAPI 
fluorescence (DNA stain).  IE2 staining overlapped and colocalized with nuclear DAPI staining, 
with no IE2 signal in the cytoplasm (Fig. 3-2).  GM130 staining is only present in the cytoplasm 
and does not colocalize with nuclear DAPI.  Thus, as expected, the two proteins unambiguously 
localized to different locations within infected cells, validating use of the same secondary antibody 
to detect them simultaneously. 
A tool for identifying mature cVACs in HCMV infections.  To further reduce 
subjectivity while enumerating Golgi rings, we collected images of numerous Golgi structures 
present in IE2-positive cells and arranged them into a gradient from less to more certain 
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assignments as cVACs (Fig. 3-3).  Using this tool as a reference while counting cVACs helped to 
more reliably identify cVACs in a quick, relatively objective manner. 
Changes in the stability of pUL103-FKBP-V5 affect cVAC abundance.  To verify that 
the UL103-FKBP-V5 virus allows manipulation of cVAC abundance in response to variation in 
pUL103-FKBP-V5 stability, we measured relative cVAC abundance in the presence and absence 
of Shield-1.  Previously, using the UL103-FKBP-V5 virus, we showed pUL103-FKBP-V5 
stability is important for cVAC biogenesis (26).  Thus, we can use cVAC biogenesis as a biological 
endpoint for pUL103-FKBP-V5 activity.  As expected, in the presence of Shield-1, Golgi rings 
form and there is pUL103-FKBP-V5 staining in the center of those rings, indicative of cVACs.  In 
the absence of Shield-1, pUL103-driven cVAC biogenesis is disrupted (Fig. 3-4 A).  The decrease 
in relative cVAC abundance in the absence of Shield-1 is quantifiable (Fig. 3-4 B).  In general, 
there are about twice as many cVACs produced in the presence of Shield-1 compared to when it 
is absent. 
Shield-1 time course experiments.  To identify the period when pUL103 is required for 
maximal cVAC abundance, we varied the period of Shield-1 presence during infection.  In each 
of the following experiments, positive controls included Shield-1 throughout infection and  
negative controls to which Shield-1 was never added; an example is shown in Fig. 3-4.  After 120 
or 144 hours, the infections were stopped and analyzed using IFA (Figs. 3-5 B-E).   
Identification of the beginning of the period when pUL103-FKBP-V5 is required for 
maximal cVAC abundance.  To determine the latest time of pUL103-FKBP-V5 stabilization for 
maximal cVAC abundance during 144-hour infections, we added Shield-1 at 12-hour intervals 
from 12 to 60 hpi (Fig. 3-5 A, Experiment 1).  There was a statistically significant difference 
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between the positive and negative controls, but no difference between the positive control and any 
of the experimental time points (Fig. 3-5 B).   
Since Experiment 1 showed no changes in cVAC abundance when Shield-1 was added as 
late as 60 hpi, we tested addition of Shield-1 at time points between 72 and 108 hpi during 120-
hour infections (Fig. 3-5 A, Experiment 2).  There were progressively fewer cVACs present when 
Shield-1 was added at time points later than 84 hpi, but in comparison to the positive control, the 
differences were not statistically significant (Fig. 3-5 C). 
To more precisely determine the latest time for pUL103-FKBP-V5 stabilization to obtain 
maximal cVAC abundance during 120-hour infections, Shield-1 was added every three hours 
between 84 and 96 hpi (Fig. 3-5 A, Experiment 3).  Compared to the positive control, fewer cVACs 
were produced at each experimental time point (Fig. 3-5 D).  There was a statistically significant 
difference between the positive control and the addition of Shield-1 at 96 hpi.   
Our results indicate that the latest time for initiation of pUL103-FKBP-V5 stabilization for 
maximal cVAC abundance during 120-hour infections is between 72 and 84 hpi.  
How long does pUL103-FKBP-V5 need to be stabilized for maximal cVAC 
abundance?  For infections initiated under conditions that stabilize pUL103-FKBP-V5, we 
determined how long pUL103-FKBP-V5 needed to be stabilized for maximal cVAC abundance 
during 120-hour infections.  Thus, in Experiment 4, Shield-1 was present from time zero and then 
removed (pUL103-FKBP-V5 destabilized) at time points after maximal cVAC formation (72-84 
hpi) and the relative cVAC abundance was determined at 120 hpi (Fig. 3-5 A, Experiment 4).  
cVAC abundance was significantly reduced when Shield-1 was removed at 84 hpi, to a level 
similar to that of the negative control, in which Shield-1 was absent for the entire 120-hour 
infection (Fig. 3-5 E).  When Shield-1 was absent from 87 to 93 hpi, cVAC abundance was slightly, 
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but not significantly reduced compared to the positive control.  Our results indicate that for 
infections initiated under conditions that stabilize pUL103-FKBP-V5, it takes between 33 and 36 
hours for the effects of its destabilization on cVAC abundance to become apparent. 
Discussion 
The work described here addresses two main areas.  The first relates to the biochemical 
and biological functions of pUL103, a protein conserved across the herpesvirus family that may 
be involved in many processes from entry to egress, including, cell-to-cell spread, cVAC 
biogenesis, and secondary envelopment.  The second relates to the processes and mechanisms 
involved in HCMV cVAC biogenesis. 
pUL103 and the important processes it is involved in represent potential targets for antiviral 
development.  For that to be realized, detailed studies are needed to determine the mechanisms of 
actions of pUL103.  As a prelude to such work, it is important to identify the periods or states 
when pUL103 is serving a particular purpose during infection.  Our objective here was to identify 
the temporal window when pUL103 is required for maximal cVAC abundance. 
In Experiments 1, 2, and 3, we found that for maximal cVAC abundance, initiation of 
pUL103-FKBP-V5 stabilization must begin no later than 72 to 84 hpi during a 120-hour infection.  
In the absence of stabilization of pUL103 during this period, it is possible that key protein 
interactions required to create the cVAC are lost.  In addition, pUL103 may exert regulatory effects 
by binding nucleic acids via its conserved putative topoisomerase domain (41). 
When Shield-1 was present from the beginning of infection (Experiment 4), we found that 
it takes between 33 and 36 hours for the effects of pUL103-FKBP-V5 destabilization to become 
apparent.  This suggests that during a 120-hour infection, pUL103 must be present after 84 hpi to 
maintain maximal cVAC abundance.   
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The combined results from experiments 1-4 suggest that the period between 72 and 84 hpi 
would be an informative period for study of the mechanistic roles of pUL103 in cVAC biogenesis 
and activity.  Such studies might include analysis of virion assembly, intra- and extracellular viral 
titers, characterization of identity shifting of endosecretory organelles and machinery prior during 
cVAC biogenesis (27), live cell imaging of viral and cellular proteins, and deep temporal and 
spatial proteomics analysis of viral and cellular proteins during this process.  We note that, while 
stabilization of pUL103 before 72 to 84 hpi is not required to achieve the maximum number of 
cVACs, it is possible that it may function early in infection in ways that are unrelated to cVAC 
biogenesis in cell culture, such as interactions with antiviral proteins of the innate immune system 
and cell trafficking (72).   
Due to lack of antibodies, we have not been able to detect native pUL103 during infections.  
However, with the presence of C terminal V5 and His tags, we are able to visualize pUL103 with 
these modifications (pUL103-V5-His).  Over a 120-hour infection, pUL103-V5-His is most 
abundant at between 96 and 120 hpi (unpublished data).  Thus, during the temporal window of 72 
- 84 hpi when we determined pUL103 is required for maximal cVAC abundance, the protein itself 










FIG 3-1 Time course of HCMV protein expression in cells infected with the UL103-FKBP-
V5 virus in the presence and absence of Shield-1.  HFFs were uninfected (U) or infected with 
HCMV pAD/Cre UL103-FKBP-V5 in the absence (-S) and presence (+S) of Shield-1 at an MOI 
of 0.1 for 120 hpi.  Shield-1 was replenished at 72 hpi.  Infections were stopped, protein 
harvested with RIPA buffer, and separated into RIPA-soluble and RIPA-insoluble fractions every 
24 hours throughout the infection.  30 µg of the RIPA-soluble samples were analyzed using 
immunoblotting.  GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as the loading 
control.  Samples were probed for immediate-early (IE1, IE2), early (UL44), and late (pUL103-
FKBP-V5) viral proteins using IE2, UL44, and V5 primary antibodies followed by goat anti-


























FIG 3-2 Immunofluorescence signals of viral nuclear marker IE2 and cellular cytoplasmic 
Golgi marker GM130 do not overlap in HCMV-infected cells.  HFFs were uninfected or 
infected with UL103-V5-His at an MOI of 0.1 for 120 hpi.  IFA was used to assess the 
localization patterns of both proteins.  DAPI stains DNA, primarily in the nucleus, and is blue.  
IE2 is present in the nucleus and detected using an IE2 primary antibody followed by Alexa 
Fluor Goat anti-mouse 568 secondary antibody that is red. GM130 is present in the cytoplasm 
and detected using a GM130 primary antibody and Alexa Fluor Goat anti-mouse 568 secondary 


























FIG 3-3 A Golgi ring gradient: a tool created to assist with discernment of mature cVACs.  
Images of Golgi rings and other Golgi structures from one IFA image of an HCMV infection 
used as a tool for assessing the presence or absence of Golgi rings representative of cVACs. 
HFFs were infected with UL103-FKBP-V5 in the presence of Shield-1 at an MOI of 0.1 for 120 
hpi. Shield-1 was replenished at 72 hpi.  Golgi is in the cytoplasm and was detected using a 








FIG 3-4 Changes in the stability of pUL103-FKBP-V5 affect cVAC abundance.  (A) IFA 
images of UL103-FKBP-V5 virus infections at an MOI of 0.1 for 120 hpi in the absence (-S) and 
presence (+S) of Shield-1.  Shield-1 was replenished at 72 hpi.  DAPI stains DNA, primarily in 
the nucleus, and is blue. pUL103-FKBP-V5 is present in the cytoplasm and detected using a V5 
primary antibody followed by Alexa Fluor Goat anti-rabbit 488 secondary antibody that is green.  
IE2 is present in the nucleus and detected using an IE2 primary antibody followed by Alexa 
Fluor Goat anti-mouse 568 secondary antibody that is red. GM130 is present in the cytoplasm 
and detected using a GM130 primary antibody and Alexa Fluor Goat anti-mouse 568 secondary 
antibody that is red.  (B) Quantification of cVACs from infections in (A).  Statistical significance 
was measured using the chi-square test (**: p < 0.01,).  n, number of cells counted.  hpi, hours 






9624 72480 120 144 hpi
cVAC biogenesis






Controls Shield-1 present 
Experiment 2
Experiment 3
























n 45 41 49 69 88 62 52














n 110 138 110 102 116 109 118





















n 77 107 81 59 88 62 61





















n 77 107 48 38 36 47















FIG 3-5 pUL103-FKBP-V5 is needed for maximal cVAC abundance between 72 and 84 
hpi.  (A) Schematic of events that occur over the infection period including changes in pUL103-
FKBP-V5 protein levels (blue-gray triangles), cVAC biogenesis (yellow bar), and Shield-1 
presence (solid lines) and absence (dotted lines).  Shield-1 was replenished at 72 hpi.  Diamonds 
at the beginning of lines indicate the beginning of infection. The circles at the end of lines 
indicate when the infection was stopped.  Positive and negative controls for experiments were 
Shield-1 present and absent from time zero, respectively.  In experiments 1, 2, and 3, Shield-1 
was added between 12 and 60 hpi, 72 and 108 hpi, and 84 and 96 hpi, respectively.  In 
experiment 4, Shield-1 was removed between 84 and 93 hpi.  (B) Quantification of cVACs from 
experiment 1, illustrated in (A).  (C) Quantification of cVACs from experiment 2, illustrated in 
(A).  (D) Quantification of cVACs from experiment 3, illustrated in (A).  (E) Quantification of 
cVACs from experiment 4, illustrated in (A).  Statistical significance was measured using the 
chi-square test (*: p < 0.05, **: p < 0.01,).  n, number of cells counted.  hpi, hours post infection.  




CHAPTER 4: FINAL CONCLUSIONS AND DISCUSSION 
History of HCMV.  Human cytomegalovirus has been recognized as a human pathogen 
since as far back as 1881, when several German scientists visualized images of HCMV-infected 
cells with nuclear (owl’s eye) and cytoplasmic inclusions (Fig. 4-1 A-C).  However, these scientists 
mistakenly thought the phenotype was caused by protozoans.  By 1932, scientists continued to 
observe cells with these inclusions, but had not yet identified their origin.  During this time a lethal, 
congenital condition was being characterized. The patients presented with petechiae, swelling of 
the liver and spleen (hepatosplenomegaly), and intracerebral calcification.  In the 25 patients with 
this condition, they all had cells with nuclear and cytoplasmic inclusions.  Because of this, a group 
of scientists from St. Louis, MO began referring to the condition as generalized cytomegalic 
inclusion disease (CID).  In 1956 and 1957 three independent labs cultured the agent responsible 
for causing nuclear and cytoplasmic inclusions in various cell types and the agent was termed 
human cytomegalovirus (44). 
Diseases caused by HCMV.  From the time HCMV was identified, much has been learned 
about the types of diseases it causes.  For those with intact immune systems, HCMV usually does 
not cause severe disease.  Healthy individuals may experience mononucleosis-like symptoms or 
none at all.  Typically, HCMV requires a deficiency in the host’s immunity for severe disease to 
develop.  Thus, the populations most affected by HCMV infections are those with 
immunodeficiencies (fetuses, infants) and those who are immunocompromised (transplant 
recipients, HIV/AIDS patients).  Immunodeficient populations may suffer from liver, lung, and 
spleen problems, petechiae, deafness, intracerebral calcification, microcephaly, and/or mental 
retardation.  Immunocompromised populations may suffer from widespread inflammation of the 
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eyes (choroid and retina), lungs, esophagus, colon, small intestine, brain and meninges, spinal 
cord, pancreas, and/or liver (64, 67).   
HCMV statistics.  HCMV is the most common viral congenital infection, as well as the 
leading cause of birth defects and childhood disabilities in the United States (49, 67).  More 
children suffer from CMV-related diseases than from more well-known congenital conditions such 
as Down syndrome, fetal alcohol syndrome, or spina bifida (16).  The virus is also the most 
common, non-hereditary cause of hearing loss in children (43).   
Current treatments for HCMV infections.  Since the discovery of HCMV, there have 
been five main drugs developed for treating these infections: ganciclovir (GCV), valganciclovir 
(VGCV), cidofovir (CDV), foscarnet (FOS), and letermovir (LTV).  GCV, VGCV, CDV, and FOS 
all target viral DNA replication.  This is problematic because antiviral resistance to one of these 
medications can lead to resistance to most, if not all.  In addition, they can be toxic, resulting in 
unfavorable side effects for the patients (9, 10, 44, 64, 67).  This is partially due to drug interactions 
between these treatments and other medications taken by the patients (46).  The toxicity of these 
drugs may also be due to off-target effects on host cell DNA replication as well.  LTV is the newest 
and most promising prophylactic treatment for HCMV infections in stem cell transplant recipients.  
This drug has been shown to be effective against several clinical and GCV-resistant strains and is 
well tolerated.  LTV affects viral DNA packaging and specifically targets the viral terminase 
complex.  There is no known human analog of the terminase complex, which may explain why the 
drug is so well-tolerated (10).  This is the direction the development of new HCMV treatments 
should be heading.  We need to be working towards more novel, specific, diverse, and less toxic 
therapeutics.   
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Future HCMV remedies.  To effectively prevent and treat HCMV infections we need 
treatments targeting both lytic and latent infections.  The current HCMV treatments target lytic 
replication and have no effect on the virus in its latent state.  For treatments of lytic infections, 
most, if not all, steps of the replication cycle should be targeted.  This strategy has several benefits.  
The first is the development of antiviral cocktails consisting of multiple drugs for more potent and 
effective treatments.  The second is plenty of drug treatment options available if patients develop 
antiviral resistance or experience side effects.  Preferably, the antiviral targets should have no 
human analogs, decreasing the chances of off-target effects.  pUL103, a tegument protein, has the 
potential to be an antiviral target for HCMV infections.   
pUL103: potential antiviral target.  pUL103 has the potential to be an antiviral target for 
treating HCMV lytic infections.  As a tegument protein, pUL103 is multifunctional and has been 
shown to have multiple roles throughout the life cycle of the virus (1, 26, 72).  Thus, multiple steps 
of the HCMV replication cycle would be affected with targeting pUL103.  Several studies showed 
in the absence of pUL103, HCMV is attenuated (1, 35, 110).  Inhibition of pUL103 would weaken 
the virus and allow the host’s immune system time to control the infection.  There is no known 
human analog of pUL103, so chances of patient side effects would be low.  In addition, pUL103 
is conserved across herpesviruses (74).  Treatments targeting it may treat other herpesvirus 
infections.  However, more research of pUL103 is needed before studies investigating its 
usefulness as an antiviral target can begin.  There is still a great deal unknown about pUL103.  
This research helps to further the knowledge of this protein. 
Summary of key research results from chapters 2 and 3.  Currently the function, 
mechanisms of action, and structure of pUL103 are unknown.  The goal of our studies is to provide 
additional information about pUL103 to help fill these gaps in knowledge.  In chapter 2, I identified 
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several residues and two potential motifs that are conserved across the three herpesvirus 
subfamilies and within the cytomegalovirus genus, respectively.  The conservation of these amino 
acids indicates they have purpose.  It suggests they are necessary for the function of pUL103; 
otherwise, they would not be maintained.  These single amino acids are suitable for mutagenesis 
because each one can be systematically examined for its contribution to the function of pUL103 
and HCMV biology.  In chapter 2, I also created a structural prediction of pUL103 that aligned 
well with catalytic and catalytically inactive nucleotidyl transferase domains.  This suggested, 
along with the presence of its conserved herpesvirus domain, that pUL103 may bind nucleic acids, 
though that hypothesis was not tested in these studies.  These experiments are necessary to 
understanding whether or not pUL103 interacts with DNA or RNA as one of its many functions.  
In chapter 3, I identified 72-84 hpi as the temporal window when pUL103 is required for maximal 
cVAC abundance and stability during a 120-hour infection.  This is when pUL103 is actively 
engaged in activity beneficial to the virus.  Given the long replication cycle of HCMV, it is difficult 
to know when mechanistic studies of pUL103 should be performed; this data shows when they 
should happen.  The information in these chapters is necessary for future studies of pUL103, which 






FIG 4-1 Various images of HCMV-infected cells with characteristic nuclear inclusions with 
halos (owl’s eye nuclei). (A) Cells that German scientists mistook for parasite-infected cells.  
(B) Cell with cytoplasmic inclusion on left side, in addition to nuclear inclusion.  Images (A) and 
(B) from reference Ho, 2008.  (C) Centered: cell with basophilic nuclear inclusion body.  Image 
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Degree: Doctor of Philosophy  
Human cytomegalovirus (HCMV) is an enveloped, single segment, double-stranded DNA 
virus.  HCMV infection causes disease in immunocompromised (HIV patients, transplant 
recipients) and immunodeficient (fetuses, neonates) populations.  Current treatments are effective 
but are either limited in use or can lead to organ damage and/or antiviral resistance, and no vaccines 
are available.  Additional antiviral targets are needed.  HCMV pUL103 is a potential antiviral 
target.  pUL103 is a conserved herpesvirus protein present in the tegument, layer of proteins and 
RNA between the envelope and capsid of HCMV virions.  pUL103 helps reorganize cellular 
secretory machinery (Golgi, endosomes) to form the cytoplasmic virion assembly compartment 
(cVAC) that is hypothesized to facilitate efficient virion assembly and egress.  pUL103 is also 
important for cell-to-cell spread and virion maturation.  The structure, function, and mechanisms 
of action of pUL103 are unknown. 
To identify amino acids important for pUL103 functions, I aligned the sequences of 14 
pUL103 homologs using MUSCLE (Multiple Sequence Comparison by Log-Expectation).  My 
data showed 12 conserved amino acids outside of the conserved herpesvirus domain.  Within the 
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N terminus there are 13 conserved residues, which shows the importance of this region and these 
residues in pUL103 function.   
To guide biological studies of pUL103, I used I-TASSER (Iterative Threading ASSEmbly 
Refinement) to predict structures of pUL103 and its homologs HSV-1 pUL7 (pUL7) and EBV 
BBRF2 (BBRF2) using their amino acid sequences.  My data showed (a) their predicted secondary 
structures are similar, (b) the predicted structure of BBRF2 differs from pUL103 and pUL7, which 
are similar, and (c) the predicted pUL103 structure aligned with the non-catalytic LIM domain of 
human terminal uridylyl transferase 4 (TUT4), a nucleotidyl transferase domain lacking catalytic 
residues.  This data suggests pUL103 may bind nucleic acids; experiments can be designed to test 
this hypothesis.   
To identify when pUL103 mechanistic studies should be performed, I determined when 
pUL103 is necessary for maximal cVAC abundance.  During 120-hour infections, I showed 
pUL103 must be present between 72 and 84 hpi.  Such studies might include analysis of virion 
assembly, intra- and extracellular viral titers, and deep temporal and spatial proteomics analysis of 




My name is Ashley Nicole Anderson.  I was born Tuesday, September 26, 1989 at Women 
and Infants Hospital in Providence, RI.  I lived on the east coast in Massachusetts with my mother, 
brother, and father until I was 6 years old; then we moved to Detroit, Michigan.   
I excelled academically from elementary all throughout high school, despite adversity.  In 
2005, I was diagnosed with systemic lupus erythematosus (SLE, lupus).  SLE is an autoimmune 
disease that disproportionately affects women, specifically women of color.  Lupus gave me 
strength and changed my career trajectory for the better.   
As an undergraduate at the University of Michigan-Ann Arbor (U of M), I continued to 
excel in my academics and had the opportunity to conduct lupus research in the laboratory of Dr. 
James Shayman under the tutelage of Dr. Robert Kelly.  In April 2011, I graduated with my 
Bachelor of Science degree, with honors, in Neuroscience.  After receiving my undergraduate 
degree, I began my predoctoral studies at Wayne State University. 
As a doctoral candidate in the laboratory of Dr. Philip Pellett, my dissertation work focused 
on the human cytomegalovirus tegument protein pUL103.  I utilized biological and computational 
studies to fill gaps in knowledge relating to the structure, function, and mechanisms of action of 
this protein.  It has been a long journey, but I have finally done all the work necessary to achieve 
my PhD in immunology and microbiology.  Though this phase of my life has come to an end, I 
am excited about what lies ahead of me. 
I accepted a post-doctoral position at the University of Virginia in the laboratory of Dr. 
Shu Man Fu.  There, I will study lupus, specifically the origin of lupus-related auto-antibodies 
(auto-Ab).  My project will focus on identifying the origin of auto-Ab to Ro60.  Anti-Ro60 are the 
most common auto-Ab in healthy normal individuals. 
